



---

## **A Review - Colorectal Cancer, Prevalence, along with Screening, Diagnosis, and Novel Therapies**

Muhammad Atif Imran<sup>a\*</sup>, Hira Shahid<sup>b</sup>, Bisma Zaheen<sup>c</sup>, Nimra Bashir Qureshi<sup>d</sup>,  
Maila Attique<sup>e</sup>

<sup>a,b,c,d,e</sup>Department of Biochemistry, Government College University Faisalabad, 38000, Pakistan

<sup>a</sup>Email: [atifimran28@yahoo.com](mailto:atifimran28@yahoo.com), <sup>b</sup>Email: [hiraach2711@gmail.com](mailto:hiraach2711@gmail.com), <sup>c</sup>Email: [bismakhan2612@gmail.com](mailto:bismakhan2612@gmail.com)

<sup>d</sup>Email: [bkhan9304@gmail.com](mailto:bkhan9304@gmail.com), <sup>e</sup>Email: [mailagoraya@gmail.com](mailto:mailagoraya@gmail.com)

### **Abstract**

Colorectal cancer is considering a communal health problem and in the whole world, its number is third in all cancers that were diagnosed. It causes a significant burden in terms of sickness and death with the estimation of seven lakhs annual deaths. In many countries of the world western way of life is rapidly adopted that is a well-debated factor for colorectal cancer and in term of primary preventive measures, it could be besieged. Comparatively slow advancement of this cancer allows severe reduction of occurrence and death rate with the help of secondary prevention. These facts motivate primary care physicians to play a key role in health plans that improve prevention and rapid diagnosis. In ancient years, the targeted therapies with combinational treatment have proven to be very effective for specific colorectal cancer patients. These therapies are epidermal growth factor, receptor inhibitor, and growth factor. As the advancements in clinic and science have visible that give new treatment options for metastatic colorectal cancer, the five-year existence rate is still fourteen percent low. But in other subtypes of colorectal cancer, the results may not be successful and not highly explored. We can reduce side effects and make the treatment effect by using alternative therapies instead of traditional therapies such as anticancer drugs, probiotics, etc. Herein, some major topics related to CRC in recent literature have been reviewed, to acknowledge its malignancy, risk, and defensive factors, along with the screening methodologies. Moreover, we also debate over preventive as well as screening strategies to fight against CRC.

---

\* Corresponding author.

**Keywords:** Colorectal Cancer; Apoptosis; Cancer Treatment; Medicinal Plants; ncRNA; microbiota; biomarkers; gene-expression profiling; agarose microbeads; metal-based drugs; probiotics; functional food; anti-inflammatories.

## **1. Introduction**

The second leading cause of colorectal cancer is colorectal cancer that is the third most commonly diagnosed cancer in the United States. Fifty-five thousand people die because of colorectal cancer and one lakh thirty-four thousand new cases are reported in 1996. If a colorectal cancer diagnosis is delayed, then malpractice action medical may result. Inactive lifestyle, extreme alcohol consumption, a diet low in fiber and high in saturated fat, genetic conditions, family history & older age are the risks for colorectal cancer. Around of these risk factors such as proceeding age cannot be altered and other risk factors such as a diet that require enormous and lasting communal educational plans to change. Through proper screening and investigation colorectal cancer could be greatly reduced as many people died and developing colorectal cancer collected by evidence in recent years. Cost-effectiveness of various test plans, who should be tested, how regularly they should be performed are some uncertainties in the selection of screening and investigation test. To assess the indication on screening and investigation of colorectal cancer and to create proper rules for clinical practice American Gastroenterological Association (AGA) is contracted by a federal agency for Health Care Policy & Research in 1994 as colorectal cancer screening rate is very low according to this evidence Society of American Gastrointestinal Endoscopic Surgeons, American College of Gastroenterology & American society of colon and Rectal Surgeon are the groups of the organization besides of AGA based on which AGA produce this document. In countries undergoing rapid economic and societal changes together with countries having western lifestyle colorectal cancer is considered one of the strongest markers of the cancer transition by replacing infection-related cancers and the high-income countries already often found it [1–3]. It (M. M. Center and his colleagues 2009; Bosetti and his colleagues 2011; Stewart, Wild, and (Eds) 2014). Mainly in South America, Eastern Europe & Asia that are the HDI (medium-to-high) countries where the occurrence and death rate by colorectal cancer now detected rapidly [1]. Where as in highest index HDI countries the occurrence and death rates by colorectal cancer have been alleviating or decreasing. The highest index HDI countries are several western Europe, New Zealand, Australia & the USA [1]. The main reason for the decrease in the occurrence rate in these countries is prevention through polypectomy and the increase in the early detection when the ill signs are reflected. Chemotherapy, radiotherapy & perfection in perioperative care are the main factors that decrease the occurrence of disease. These factors play a uniform role in decreasing the death rate of colorectal cancer in most income settings [4,5]. It is expected that the global load of colorectal cancer is increased by sixty percent given the sequential outlines and demographic plans more than 1.1 million cancer death by 2030 and 2.2 million novel cases [6]. The evolution of colorectal cancer from a worldwide vantage point is consequently overbearing by understanding its existing pattern. In Colorectal cancer occurrence and death, we define geographical variation in this study although in one hundred and eighty-four countries it was defined, and time tends in thirty-seven countries. By linking the conclusions to future diagnoses, the problem can be dropped through cancer treatment and care. The worldwide occurrence and death rates of colorectal cancer for men are higher than for women. For everyone lac population, there are twenty-one new cases and ten deaths for men as compared to seventeen new cases and nine deaths for women. Colorectal cancer secured the third rank in occurrence for men and it ranked


second for women, men have lung and prostate cancer and women commonly have breast cancer [7,8]. The geographical discrepancy of colorectal cancer occurrence is above ten folds in the whole world [9]. If there is one lakh population then the occurrence rate of colorectal cancer for men is 44.8 and for women, it is 32.2 based on the age standardization and it is also observed that the New Zealand & Australia have highest occurrence rates of colorectal cancer and after these North America and Europe have high rates. In Africa the occurrence rate is low and it is 3.0 for women and 3.5 for men if we have a one lac population estimated in Western Africa [8–10]. Before the fourth era of life, the occurrence of colorectal cases fairly infrequently increases with age [8,9]. That is the main reason the people having age more than fifty years targeted with screening programs. People having ages between forty to forty-four have an alarming increase in the occurrence rate according to the current study and this lower age is the warning reflection of suggested screening [11,12]. In economically developed countries, the death is gradually decreased whereas in developing countries the death rate is either alleviating or constant [8,13]. These all, for example, routine risk factors, availability & proper care show the diversity in services of screening [13]. In Middle West Africa highest death ratio is seen while according to the report the highest death ratio is found in Central-Eastern Europe [8,14]. We collect all the conversant data on the recent colorectal cancer medicinal literature and intended to make a description review literature in that study. Delivering accessible data to primary care physicians & gastroenterologists after recapping it is the main objective for a well considerate of the recent evidence with a complete circumstantial.

## **2. Sources and Methodology**

This literature consists of a diligent review-writing led through the hunt of specific keywords in digital databases, including PubMed, Google Researcher, Elsevier, Scopus, and Web of Science. Keywords used in this review are Colorectal Cancer; Apoptosis; Cancer Treatment; Medicinal Plants; ncRNA; microbiota; biomarkers; gene-expression profiling; agarose microbeads; metal-based drugs; probiotics; functional food; anti-inflammatories. Many latest articles were decided after the separation and evaluation through the association of the above keywords. These relevant kinds of literature were based on distinct criteria including CRC, diagnosis, biomarkers, recent treatments, prevention, etc.

### **2.1 Origins of CRC**

Many inherent and extrinsic factors are involved in the initiation of colorectal cancer. Long-lasting inflammation, exposure of alleles connected with family history, pre-existing mutations & accretion of novel mutations are some of the factors labeled in Figure 1. In the pathogenesis of colorectal cancer family history is not elaborated because the majority of colorectal cancers are irregular about seventy-five percent [15]. TP53 (tumor protein 53), KRAS (Kristen's rat sarcoma) & APC (adenomatous polyposis coli) are the oncogenes and the genes that suppress tumor and cause communal mutation which involve irregular colorectal cancer cases sixty percent, forty-three percent & eighty-one percent correspondingly [16]. In the pathogenesis of colorectal cancer, the role of genetic variations has been widely studied [17–19]. Most mutations act in a particular order that includes colorectal cancer, to an adenoma, it defines the development of normal intestinal epithelia by controlling adenoma-carcinoma sequence, ultimate metastatic tumor & aggressive carcinoma also included in these mutations.



**Figure 1:** Intrinsic and extrinsic factors contributing to the pathogenesis of colorectal cancer (CRC).

Round about ten to thirty percent of colorectal cancer are concerned with family history [20,21]. FAP (Familial adenomatous polyposis) & Lynch syndrome that is the colorectal cancer of hereditary nonpolyposis are examples of the most frequent disorders of congenital colorectal cancer having cases of two to four percent & one percent accordingly [20]. The inflammation that is pre-existed usually does not develop ninety-six percent of all colorectal cancers while some inflammations play their role in the development of colorectal cancer such as long-lasting inflammation, the inflammations that elicit tumor, TME (tumor microenvironment) & immune cells that are partly adapted, mainly by seeing their interaction with gut dysbiosis we can understand their action [22–27]. Cancer that is associated with colitis known as CAC can be considered by its interference with inflammation and it is a specific set of colorectal cancer and for all colorectal cancer, it contributes about one to two percent [28]. Severe inflammation in the small intestine or colon or both caused origination of CAC, severe inflammation of colon occurs in CD (Crohn’s disease) and severe inflammation of small intestine occur in UC (ulcerative colitis) when immune cells activate excessively then they enrolled in the production of inflammatory cytokines and the basic cytokines that involve in the spreading of inflammatory environment that may be a premalignant environment are IL-23, IL-17, IL-16 & TNF [29]. The genes that control immune activation and subsequent responses produce mutation that involves in IBD (Inflammatory bowel disease, the factors that regulate ER stress involve TNFSF 15, IL12B, IL10, TNFSF8, IL7R, JAK2, IL2 & DENND1B and those that regulate the transport of organic ions are SCL11A1 and those that transfer bile, salt & glucose are SLC9A4, XBP1 & SCL11A [30]. Microenvironment that shows inflammatory action is exhibited by both CRC & CAC, but it appears to be very difficult in which inflammation & tumorigenesis happen. Most of the inflammations follow tumorigenesis in colorectal cancer. tumor development is initiated by the environmental factors that cause mutation in colorectal cancer and the further DNA damage produced as the reaction of oxygen and nitrogen species occur and these damages are caused by the inflammatory cell’s activation [29,31]. Additionally, tumorigenesis is led by inflammation in CAC. The release of proinflammatory cytokines & immune cell activation induces inflammation that further led to the induction of mutation and damage of DNA in CAC [29]. CAC & CRC both have similarities in their mutation, but these mutations have a difference in timing and order, in colorectal cancer early APC & late APC displayed these mutations on the other hand in CAC early TP53 & late APC describe these mutations. The inflammation that elicits tumor is the main contributor to colorectal cancer, inactivation of APC that cause loss of the function of normal barrier that derives the tumor formation

[22].

## **2.2 Epidemiology**

Colorectal cancer is worldwide most communal cancer and each year it diagnoses novel cases in million about one or two million that's why colorectal cancer has 3rd rank for its communality and seven lakh deaths make it rank 4th for its common source of death, only liver, lung & stomach cancers can be exceeded. If we talk about gender about nine percent of melanoma is caused by colorectal cancer in females and males, it is ten percent [32]. Per annum, two lakhs of novel cases describe that the occurrence of colorectal cancer has been mounted and its increase started from 1990 to 2012. The percentage of many cases that are detected in Western countries is fifty-five percent and in the previous few years as certain countries have rapid advancement there seen a variation in this propensity [33]. In 2010 thirty-three percent of deaths occur in Western countries across the world all because of the signs of progress about colorectal cancer that are made in the health system and advancement in the plans of screening [34]. In 2016 the death rate due to colorectal cancer is 49,190 and the new cases reported are 134,490 all these cases and death rates make 2016 not exciting.

## **2.3 Etiology**

When a mutation occurs in a particular gene it triggers the onset of colorectal cancer as we see in other types of cancer. Within oncogenes, those mutations may appear and may be in the genes that suppress tumor & in the DNA repair mechanism gene [35]. Colorectal cancer cause mutation and on this basis, we can say that it is widespread, have a family history & is genetically inherited. During the lifetime, the syndromes that are inherited are not caused by point mutations these mutations have their effects on progenies of individual cells or these cells themselves. The cause of sporadic cancer is point mutation and in all colorectal cancer, its percentage is seventy. Molecular pathogenesis is heterogenous for irregular distortion the reason behind this heterogeneity is that the genes that are targeted by mutations are dissimilar [35]. The definite series of transmutations are followed by colorectal cancer cases of about seventy percent that are then decoded in a definite morphological sequence, the finishing point of this sequence is a carcinoma stage, and its starting point is adenoma formation. 1st transmutation happens in APC (Adenomatous-polypoidosis-coli), which is a tumor that suppresses gene, activating the development of adenomas that show no malignancy, comes under the term polyps. Almost all adenomas adenoma of about fifteen percent are likely to be encouraged a stage within ten years that stage is carcinoma. These APC mutations are monitored through alterations in DCC and KRAS & finally TP53 [35]. Inherited cancers involve only five percent as compared to all colorectal cancer. cancers of this type may be triggered through the genetic transformations which upset one of all alleles of genes that are mutated, which means that point mutation within another allele may cause the phantom of cancer cell, afterward, the state of carcinoma. For a generation of a more precise organization of the inherited malignancies, 2 groups, i.e., polyposis & non-polyposis types, have been recognized. FAP is included in the polyposis variation mostly that is categorized through the development of manifold potentially colonel malignant polyps [36]. HNPCC (Hereditary-non-polyposis-CRC) is connected through transmutations that occur in the mechanisms of DNA repair. Lynch syndrome is included in the Chief sources of HNPCC which alteration is occurring through inherited transformations even alteration in only one allele that is programmed the repairing proteins of DNA

like PMS2, PMS1, MLH6, MLH1, and MSH2. The most common disorder in a group of HNPCC is lynch syndrome and accounts for 2 to 3 percent of all the CRC cases [36,37]. CRC that includes family history is twenty-five percent of total cases of CRC & it is similarly triggered by the inherited transmutations, though not categorized as the inherited tumors per se as they may not be incorporated in any variant of inherited cancer [20].

#### **2.4 Molecular Pathways of Colorectal Cancer**

An imperative feature OF colorectal cancer is Genomic variability. The mechanisms of the pathogen are a source of the condition that can be incorporated in 3 different paths, viz. CIMP (CpG-island-methylator-phenotype), microsatellite-Instability (MSI) & CIN (chromosomal-instability). The CIN path, also measured as a classical path because it characterizes the reason of 80–85 percent of all the cases of CRC [38], is considered by disparities in chromosome number, so important to aneuploidy lumps along with heterozygosity (LOH) loss. The underlying mechanisms of CIN comprise changes in segregation of chromosomes, dysfunction of the telomere, and response to DNA injury, which disturb crucial genes included within the preservation of cell job that is precise, like PI3K, APC, TP53, and KRAS among the others. Mutations in APC of cause beta-catenin translocation to the nucleus as well as drive transcription of certain genes concerned in invasion and tumorigenesis. Lastly, function loss changes in TP53 that encode the p53, checkpoint of the chief cycle of the cell, the foundation of an unrestrained entrance in the cell cycle [39]. Mutated genes in tumors with MSI contain PMS2, MLH1, MSH6, PMS1, and MSH2 (Boland and Goel 2010). Generally, tumors of MSI have an improved prognosis as compared to sporadic tumors [40]. Generally, tumors of MSI have an improved prognosis as compared to sporadic tumors [41]. Of 39 epigenetics and Genetics are not special in CRC, and they both collaborate in progress, with greater methylation measures than point mutations normally present [42]. An illustration of mutual consequence of epigenetics, as well as genetics developmental scanner of CRC, is the manifestation of BRAF transformation and MSI in numerous CIMP cancers [43].

#### **2.5 RISK DYNAMICS**

The chance for emergent CRC may be augmented by both the acquired/environmental and genetic factors. Though the influence of genetic predisposition in a person is far greater as compared to acquired causes influence, massive mainstream of CRC cases might be prohibited through alterations in factors of ecology [44]–[46]. The constructive method of cataloging CRC factors of hazard is the isolation of those that spot screening mentions from the ones which did not. Transmissible disorders, bowel diseases of inflammation, and family history are the major risk factors that disturb screening recommendations [47]. Practically, factors of risk, by which screening isn't disturbed, are primary preventive schemes aim [44]. Hereditary CRC disorders include frequent precise genetic syndromes which are related to the advancement of CRC, overall including approximately 10 percent cases of CRC. A key common kind is heritable-non-polyposis colorectal cancer that allegedly includes merely two to five percent of CRC cases [48,49]. Clan history, additionally, to inherent diseases so far identified, establishes very noteworthy risk factor to developed CRC, seems to include up to 25 percent cases. Though the under observation mechanisms are not understood completely, studies reveal that persons with first-degree family associates identified with colorectal cancer have 2-3 times more chances of

CRC development as compared to the universal population [48–51]. Though CRC, when compared with further public tumors, comprises a huge percentage of hereditary cases, the sporadic cases are in majority, including up to 70 percent. Risk issues concerned in the sporadic syndrome process are mostly acquired or ecological. The western way of life, alcohol intake, and smoking, certain nutritive habits, and obesity are amongst the greatest risk factors for colorectal cancer.

### ***2.6 Primary prevention***

Expectedly, a vital etiological colorectal cancer role is ascribed to lifestyle factors, as, mentioned earlier, the majority of cases of CRC cannot be linked to family or hereditary aspects [44,45,52]. aspects (Chan and Giovannucci 2010; Platz and his colleagues 2000; Bingham and his colleagues 2003). Well-discussed risk feature for CRC is Western routine, as researchers readily observed that colorectal cancer occurrence was steadily greater in developed countries [52]. The consideration was more reinforced by intensifying prevalence in the poorer areas because the western routine was accepted. Food has been a widespread focus for colorectal cancer investigation for the previous few eras, together with its possibility as a protective and risk factor. Many researchers have claimed protective factors of food higher in fiber, while other readings presenting a decrease in colorectal cancer occurrence up to 50 percent. However, many current reports have elevated misgivings about this disagreement, which are leaving queries of how defensive nutritional fibers are, exposed for upcoming prospective readings to response [53,54]. Several writers have declared defensive vitamin D and calcium role, and for the further less verified nutritional factors like omega-3-fatty acids, folate, vitamin B6, magnesium, and garlic. While frequent ingesting of fat and red meat has been related to enlarged risk for CRC development [55–57]. Chubbiness is unswervingly linked to augmented peril for CRC development, together with poorer results succeeding analysis. An analysis of the 29 readings reported that every five kg/m<sup>2</sup> incremental rise in BMI is conveyed by CRC rate increase of 24 percent in males while in females with a percentage of nine [58]. Relative to healthy figure weight, the unvarying bodily bustle is revealed to decrease CRC frequency even further, with readings revealing up to twenty to thirty percent lesser developing hazard [59,60]. Alcohol Consumption as a threat to colorectal cancer is a provocative matter, particularly while mentioning moderate or light intake, however, studies steadily reported more peril of development of colorectal tumor amongst persons with modest to hefty consumption [61]. Smoking of Tobacco is exposed to double the risk of colon tumor diagnosis as well as to consequence to poor results leading to cancer identification, which lead authors for a recommendation of more concentrated screening amongst the smokers [44,62]. Though no believed chemo defensive indications occur presently, several pharmaceutical representatives have revealed preventive things against CRC. COX-2 and Aspirin the discriminating inhibitors are amongst the most examined mediators concerning CRC stoppage, & their steady usage has publicized the ability to diminish frequency in persons mutually at increased along with average menace [63,64]. In the common population, perils from procedure look like overshadow assistances, nevertheless several sponsor practice in assured persons at augmented menace for a colorectal lump [65].

### ***2.7 Screening/secondary prevention***

Plug that years are taken by maximum colon tumors to grow succeeding Adenoma - Carcinoma sequence - certificates decrease the death of CRC via screening, whichever through initial removal and cancer detection

and removal or detection of precancerous cuts. Unevenly 3 classes of CRC screening tests are there: endoscopic tests, stool-based & imaging. Though stool-based examinations can decrease death rates by initial uncovering of the asymptomatic cancerous abrasions, endoscopic tests and imaging are proficient in further diminishing CRC prevalence by sensing precancerous imaging as well as cuts.

### ***2.8 Trials based on stool***

A blood test of Guaiac based on fecal occult Depend upon the alpha-guaiaconic acid characteristics, a compound that is phenolic removed from Guaiacum trees, gFOBT (blood test of Guaiac-based on fecal occult) may perceive heme incidence (blood hemoglobin) of stool trials. Guaiac paper originates the  $\alpha$ -guaiaconic acid turned blue after oxidization is the application of hydrogen peroxide. Change into blue color becomes obvious in seconds when the reaction is catalyzed by heme (if existing), this reaction normally takes time [66–68]. Most often CRC screening across the world is this bio reactive method which is projected as a CRC screening test nearly before half-century [68]. gFOBT, unfortunately, bears many disadvantages while it is cost affordable and noninvasive. For the observation bias, the interpretation of the result is subjected. Though stern dietary precincts which were projected in past appear to be recognized as pointless, any peroxidase may catalyze the reaction, like heme present in meat, or false-positive outcomes may clue to needless colonoscopy [66,69]. While large dose ascorbic acid ingestion (vitamin C ingestion) false-negative results can occur [70]. For the achievement of satisfactory occult blood sensitivity, individuals need to offer 3 serial stool models in addition to dietary constraints related to g FOBT preparation [71]. The labors for introduction to the novel as well as greater sensitive guaiac-based quizzes lead to lesser specificity are reported by varying specificity & sensitivity among studies & the diverse industrialist sorts [72]. As advanced adenoma sensitivity is comparatively low and they do not bleed so polyps cannot be finally detected by this examination [73].

### ***2.9 Imaging tests***

#### ***2.9.1 Double-contrast barium enema***

The colon was studied via X-rays found after transrectal attachment of barium covered on the mucosa as well as distending colon with air in double-contrast barium enema (DCBE). The DCBE use has been intensely abridged as a new method of imaging now accessible although, it is measured as a benign technique and frequently used in preceding. False affirmative consequences may result because of scanty preparation of bowel, the testified sensitivity of the DCBE for hefty polyps (> ten mm) is about 50 percent only [74,75].

#### ***2.9.2 Computed tomographic colonography***

Upon computed tomography construction or MRI of air ballooned colon this technique was described firstly greater than twenty-year before and thus offers 2 to 3-dimensional endoluminal descriptions for colon [76,77]. For detecting CRC in specificity and sensitivity terms CTC is concluding a novel CTC technique in colonoscopy developed though, studies varied the described indicative value of CTC [78]. The overall specificity and sensitivity of CTC are lower than colonoscopy values that are 80.3% and 66.8% respectively in a recent meta-analysis. This meta-analysis exhibited more specificity or sensitivity (respectively 87.3% or 91.2%)



for polyps > 10 mm [79]. CTC requires no sedation and has very little bowel perforation risk seemed that patients more preferred it than the colonoscopy technique. variable diagnostic performance occurs when a patient is exposed to radioactivity, or a dearth of unvarying approaches, CTC entails supplement colonoscopy afterward affirmative consequences on the other hand (to perform excision/biopsy)[78,79]. With an ingested contrast agent newer techniques have testified involving laxative-free CTC with the use of “fecal-tagging” although, an issue has been needed for violent preparation of bowel [80]. Numerous authors involve in the advantages of CTC in the prospective of discerning extracolonic-pathology within the asymptomatic individuals, but this dispute is provocative since these discoveries may occasionally lead to needless patient concern, costly inquiries as well as overdiagnosis.

### ***2.9.3 CEE: (Colon capsule endoscopy)***

CCE process for screening of colorectal cancer was firstly announced in the year 2006, approximately comprised of engulfing a pill-designed trick that skillfully takes snaps of GIT as it moves from this [81]. Firstly, CCE has not gained noteworthy acceptance equally as a screening apparatus for colorectal cancer, largely due to its charge and comparatively low analytic value than colonoscopy [82]. Subsequently initiation of 2nd generation-CCE (CCE-2) within the year 2009, CCE issue has to turn out to be very widely held in the literature of medicine [83]. Testified ordinary specificity & sensitivity for the CCE-2 is correspondingly 86 & 71 percent since the year 2012 it has provoked an acceptable method of screening for CRC of Gastrointestinal Endoscopy in the culture of Europe [84]. As Paralleled to the colonoscopy, endoscopy could be a slice more desired by the patient, however, this method is expensive, shortages expurgation/ surgery capability as well as needs highly destructive preparation of the bowel [84,85].

## **3. Endoscopic examinations**

### ***3.1 Flexible sigmoidoscopy/FS***

FS permits the skilled physician to envision the distal GIT up to splenic flexure, with an application of a flexible endoscope of 60 cm long [86]. Negligible bowel preparation is needed by FS, with no intake limitations or sedation, & may be achieved by non-gastroenterologists (i.e., PCPs) even by skilled fosters. Visibly, this is incapable of perceiving lesions in the proximal part of the colon that marks this wanting in the issue of sensitivity when compared with the method of the colonoscopy [87]. In a meta-analysis, the FS seemed to condense CRC frequency and death among screened persons, by 32 & 50 percent correspondingly [88].

### ***3.2 Colonoscopy***

The traditional colonoscopy method provides picturing of complete large bowel & a distal portion of the small bowel via application of a flexible endoscope, of length 120 to 160 cm. It also offers the aptitude to expunge or biopsy perceived lesions through the same process. Regrettably, it is an expensive and risky method; it also entails sedation plus widespread bowel preparation. The reported frequency of chief complications, like bleeding or perforation of the bowel, is about 0.1-0.2 percent but could develop expressively higher during excisions or surgery performance and in comorbid or elderly patients [89].

#### **4. Prevention: implementation of screening and pcps function**

This is believed that secondary and primary prevention may meaningfully reduce the burden of CRC. Past spans scientific investigation has presented, mentioned earlier, a multiplicity of choices for screening of CRC and better consideration of protective and risk factors for CRC development. Regrettably, underutilization of the screening, as well as lack of defensive policies, were presented. Certain republics of Europe still have no implementation of national programs of mass screening, while less rates of participation have been presented by others [90,91]. In the US, there is a noteworthy diminution in incidence & mortality succeeding widespread screening operation, however, overall screening application is below the national criteria. Furthermore, it is reported uninsured persons in the US and individuals of short socioeconomic or scholastic status express lower rates of participation. Furthermore, it is reported uninsured persons in the US and individuals of short socioeconomic or scholastic status express lower rates of participation. Many scholars attempted to the identification of CRC causes, underutilization of screening, and methods to boost it. Persons, in numerous studies, have exposed low consciousness regarding screening of CRC and its prominence by [90], specific affected individuals presented little attention in the selection of CRC, while few conveyed faith that colon cancer screening concerns high characters of risk along with persons not following the healthier way of life. A systematic review by [92], strongly suggestive of how significant public consciousness is for screening of CRC contribution was “Presidential Influence”, a term specified to designate the rise in CRC-screening participation of USs’ residents after President of a nation, Ronald Reagan, analyzed with colorectal cancer in the year 1985 [93]. Parallel reports of the effect of public number declarations on melanoma have been prepared, nonetheless, data demonstrated that evidence is given infrequently and in a disorderly manner leads often to diminutive term consequences and over- or misutilization of the screening facilities [94,95]. At health-care-systems level, possibilities and barriers for augmenting CRC screening participation are further obvious. Numerous studies have shown organized-mass-screening-programs efficacy, exclusively while using reminders of the patient. Participation frequency has also been seemed to be more enhanced while PCPs are included in the solicitation process. Findings from readings have led authors to advocate informational promotions that raise awareness of public awareness for screening [96]. Another interesting discovery in the works is “usual-source-of-care” patients, which are more probably to be selected for CRC [92]. The supplementary climaxes PCPs reputation as well as GPs family in care schemes of modern fitness. The investigation has designated fences on PCPs level, in certain cases with troubling discoveries. Recommending the rates of screening by the PCPs remain less [92,97]. Numerous PCPs reviews described a dearth in knowledge and training, as well as few, have even testified not discovery screening as an operative. Intercessions through the organization of the system of health care, PCPs edification on the CRC screening, procedures of counseling and prevention, along with the will of public consciousness, then, severely decline the colorectal cancer encumbrance [98].


#### **5. New Molecular Discoveries in Colorectal Cancer (CRC)**

##### ***5.1 Effect of Genomic Abnormalities on CRC Consequence***

Novel gene techniques endorsed a vast variety of the genomic deviation identification involved in CRC. Thus, though transmutations are the major genomic deviations, numerous chromosomal translocations and changes

can also often find in colorectal cancer. All those deviations disturb significant paths (MAPK/PI3K, WNT, and TGF- $\beta$ ) & cell tasks (maintenance of cell cycle and TP53) [99] Figure 2.

The passageway of WNT serves the main function in the differentiation of stem-cell and cell development. That is why cancer development can be caused by changes in these passageways. WNT passage changes in colorectal cancer are associated with the debilitated tight connections, leading to an abridged cellular bond hence helps metastasis and migration [100]. The chief genomic anomaly in colorectal cancer related to the WNT pathway is mutations in APC, though several other changes can aim this path. Additionally, genomic modifications in the WNT path are not limited, & tumors protecting changes in the APC can also lead to the other usual shifts [99]. Despite being the most unpopular altered gene, colorectal cancer is not indicated by APC because of a high incidence of changes among cases of CRC and the extensive variety of alterations found in the gene [101]. Beta-Catenin, also included in the passage of WNT, may not be usually beneficial for prediction because in colorectal cancers this is frequently overexpressed [101]. Though over-expressive c-MYC, which is activated by the instigation of the WNT path, is reflected to be a marker of metastasis and a good factor of the survival-related prognostic [102,103] The PI3K and MAPK paths are involved both in the survival and cell proliferation. Pathways affected by these changes so confer the proliferative compensations on lump cells. BRAF, PIK3CA (PI3K) & KRAS, alterations are the most common forms of colorectal cancer. Changes in KRAS codon 13 exons 2 are related to lower survival as well as poor prognosis [104], while mutations in codon 12 exon 2 are linked with more progressive metastasis and tumors [105]. Additionally, mutations in BRAF also have a deprived prognosis linked to fewer rates of survival, unstable tumors of microsatellite [106–108]. Though the most unpopular mutation in BRAF in several cancer sorts is BRAF V600E mutation, which may be a poor prognostic measure in the cancer of metastasis [41], it is nonetheless a hopeful target of personal remedy, & mishmash of specific inhibitors of BRAF V600E along with other inhibitors of MAPK/PI3K path has been revealed to be many operatives for treatment of metastatic CRC [109]. In divergence, KRAS & other fewer common mutations in BRAF are related to the resistance of therapy, therefore failure in monotherapy leads to a deprived prognosis [110]. Novel groupings with inhibitors of PI3K and MAPK path are desired in mutated tumors of BRAF or KRAS, which is limited. Though changes in PIK3CA are a moreover common piece in CRC, the relation between CRC and PIK3CA result is not so well recognized as those including BRAF or KRAS. Nonetheless, mutations in PIK3CA are linked with a shoddier prognosis after accompanied by mutations in KRAS [111]. Similarly, tumors of combined transformations in exons 20 & 9 of PIK3CA may have the worse upshot as compared to tumors protecting only one of those alterations [112]. Additionally, PTEN loss, which down normalizes the pathways of PI3K, in primary cancers is meaningfully linked with poor persistence in metastasis and an enlarged demise risk [113].



**Figure 2:** Molecular pathways involved in colorectal carcinogenesis.

In consequence, molecular characterization of somatic DNA aberrations is a helpful strategy to improve prognosis prediction and therapy selection of individual patients, constituting one of the most important bases for modern and personalized medicine.

**6. ncRNA role in CRC**

Molecules of RNA that are Non-coding (ncRNAs) are transcribed from non-coding regions of the genome, so are deficient in an ORF and not translated to proteins. In previous little years, numerous different kinds of ncRNAs are recognized and related to numerous cell tasks. For example, tRNAs along with rRNAs serve a role in mRNA translation, snoRNAs are included in modifications of rRNA, snRNAs initiate splicing & both miRNAs or siRNAs (small-interfering-RNA) control expression of the gene [114]. In this milieu, miRNAs are among the most premeditated epigenetics features in cancer because of their significance in the regulation of the expression of the gene.

These binding of miRNAs with 3’UTR regions of numerous mRNAs, that’s why encouraging the dilapidation or translation is repressed, so linking CRC to different deregulation of miRNAs Table 1. Among the newest ncRNA’s field discoveries are lncRNAs, conveyed in countless genome loci and control gene expression within cytoplasm and nucleus. In the nucleus, these may alter epigenetic indicators by suppressing or activating chromatin alteration proteins like DNMT3A, while in the cytoplasm, these may serve as miRNA distraction, translation, or regulating splicing [115].

Consequently, in proliferation processes as well as in cellular differentiation crucial role is served by lncRNAs that are closely related in cancers. For the previous years, and obligations to improvement in high output sequencing tools of the genome, novel lncRNAs are related generally with cancer, & with the CRC particularly. Some most vital kinds are offered in Table 2. In circumstances of physiology, expression of a gene is regulated by lncRNAs, alternative splicing or imprinting of epigenetics, performing as tumor suppressor genes or proto-

oncogenes. While the performance of lncRNAs like proto-oncogenes, gene upregulation may be caused by overexpression with a crucial role in tumor progression, like MYC and genetic factor of the signaling pathway of WNT [116]. When lncRNAs perform as proto-oncogenes, the overexpression may lead to gene upregulation with a crucial role in the progression of the tumor, like MYC and genes included in the signaling pathway of WNT [117]. Likewise, when serving as suppressors of the tumor, lncRNAs control the p53-dependent gene expression in normal circumstances. So, while the reduction in expression of these lncRNAs, the gene expression in the switch gets changed and the resistance of cells is improved against apoptosis, the propagation is aggregated [118].

The ncRNAs role may be improved by manifold inherited alterations in epigenetics and genetics additionally basic differences and procedures of transcription; these all aspects subsidize the deregulation as well as have etiological implications or pathophysiology of tumor.

In addition to transcriptional regulations and structural variations various epigenetic and genetic mutations that are inherited can modify the role of ncRNAs. In the pathophysiology and etiology of cancer, all these factors are concerned and subsidize their dysregulation. Multiple signaling pathways that are related to cancer are altered by ncRNAs dysregulation. To attain a well understanding of their role in colorectal cancer more mechanistic, functional, and structural categorizations should be done because of the complications in their characteristics of the structure and their three-dimensional, sequential, and exact patterns of expression. ncRNAs, obligations to the tissue-specific-signature & the specific expression configuration in cancer, have arisen as a great aptitude to develop non-invasive and accurate biomarkers for the initial CRC-detection & prognosis prediction.

Definite 12 miRNAs (like miR-7, -17, -214, -20a, -21, -199a-3p, -92a, -196a, -96, -106a, -183, -134) exhibited higher levels of expressions in samples of stool from CRC individuals than those from the healthy ones, while 8 miRNAs (the miR-9, -29b, -938, -127-5p, -222, -138, -143 and -146a,) were revealed to be depressed regulated [141]. Mixing miRNA may also establish significant biomarkers for colorectal cancer screening as well as the prognostic appraisal. Modifications in blood-base-miRNAs have also been perceived in CRC individuals, & they seem to have greater sensitivity and not more precise than the fecal-miRNAs for diagnosis of CRC. On the other hand, though numerous studies have been established the connotation between definite ncRNA & clinicopathological properties, numerous confines prevent their clinical usage.

**Table 1:** Micro-RNAs' participating in Colon Cancer (CRC)

SR.	miRNAs Name and their Target	Micro-RNAs' Functions
1.	MIR34-A (E2F5, SIRT-1, and FMNL-2)	Acetylation of p-53 (induction and inhibition)
2.	MIR-143 (KRAS and DNMT)	The proliferation of cell and their induction
3.	MIR-135 (APC)	To Suppress the WNT pathway
4.	MIR29 {DNMT-3 (A & B)}	To Reduce the methylation
5.	MIR21 targets PDCD-4	Promotion of metastasis and its invasion
6.	MIR345 targets BAG	Invasion as well as induction of cells' proliferation
7.	MIR148-b (CCK-2R)	The proliferation of cell and their induction
8.	MIRLET7C (PB-X3, KRAS, and MMP-11)	To induce metastasis
9.	MIRLET-7A (Ring finger of NP-95 ICBP-90)	The proliferation of cell and their induction
10.	MIR4995p to PDCD-4 along with FOXO-4	Inducing metastasis
11.	MIR92 to KLF-4	To migrate and promote cell growth
12.	MIR126 to P85-beta/PIK2R-2, SPRED-1	To migrate, invade, and inhibit proliferation of cell
13.	MIR320 to PDCD-4 and FOXO-4	To inhibit the proliferation of cell
14.	Family of MIR200 to JNK-2	To induce the sensitivity to Chemotherapeutic drugs, to inhibit the growth of the tumor along with metastasis
15.	MIR9 to TM4SF-1	To invade and to suppress the migration of cell
17.	MIR503 to sense Ca receptor	To migrate, invade, and induce proliferation of cell
18.	MIR181-b to RASSF-1A	Enhancement of cell survival and to proliferate
19.	MIR497 to VEGFA	To inhibit invasion and migration
20.	MIR152 to PIK-3R3	To suppress the cancer
21.	MIR187 to PTK-6, SOX-4, and NT-5E	To prevent the EMT and to inactivate the TGF-beta pathway (epithelial-transition of mesenchymal)

**Table 1 Continue**

SR.	miRNAs Name and their Target	Micro-RNAs' Functions
22.	MIR519 to Orai-1	To suppress the cancer
23.	MIR155 to Factor-1 box transcription (HMG)	To induce the beta-catenin pathway/WNT which involves in cancer suppression
24.	MIR497 to KSR-1	To induce the sensitivity to Chemo drugs, to inhibit the growth of tumor cells
25.	MIR375 to Bcl2	To inhibit the cancer progression
26.	MIR1246 to CCNG-2	To induce metastasis and growth of cell
27.	MIR140-5p to VEGFA	To inhibit the cancer progression
28.	MIR144 to GSPT-1	To inhibit the ability to proliferate and migrate
29.	MIR638 to D-1 Phospholipase	To inhibit the proliferation of cell
30.	MIR99B-5p to mTOR	To inhibit the formation of metastasis
31.	MIR101 to SphK-1	To inhibit the cell growth and to increase the chemo-sensitivity of paclitaxel
32.	MIR20-A to TIMP2	To inhibit the cell growth and to increase the chemo-sensitivity of paclitaxel
33.	MIR20-A to TIMP2	To induce the transition of epithelial-mesenchymal (EMT)
34.	MIR409-3P to GAB-1	To inhibit the growth of the tumor along with metastasis

**Table 2:** Long Non-Coding RNA in Cancer and CRC

Sr.	Name, length (kB), and Locus	Dysfunctional Type	Role in Cancer	References
1.	H-19, 2.3 kB, Chr-11p-15.5,	To over-express	To downregulate the tumor suppressor (RB)	[119]–[121]
2.	HOTAIR, 2.2 kB, Chr-12q-13.3	To over-express	Reprogramming of chromatin state and induction of metastatic progression	[122,123]
3.	MALAT1, 7 kB, Chr-11q-13.1	To over-express	To induce the death resistance of cell and to increase metastasis, abnormal mitosis, and invasion	[124]
4.	MEG3, 1.6 to 1.8 kB, Chr-14q-32	To down-regulate	To downregulate p53, to induce proliferation, and to inhibit apoptosis	[125]
5.	CCAT-1, 2.6 kB, Chr-8q-24.21	To over-express	To induce expression of MYC. Cell migration and proliferation enhancement. Also, G1 inhibition.	[126,127]
6.	CCAT-2, 0.4 kB, Chr-8q-24	To over-express	To induce instability of chromosomes, the proliferation of the cell, and invasion	[128]
7.	CRNDE, 10 kB, Chr-16: hcg-1815491	To over-express	Role in Warburg effect. Greater risk of CRC	[129]
8.	OCC1, 1.2 to 1.3 kB, Chr-12121.1	To over-express	To induce resistance of apoptosis and cell proliferation.	[130]
9.	LIT-1, 91 kB, Chr-11q-15.5	Imprinting loss occur	—	[131]
10.	PTENP-1, 3.9 kB, Chr-q-13.3	To down-regulate	To enhance the level of PTEN and reduce the growth of cell	[132]
11.	MYLKP-1, 106 kB, Chr-3p-12.3	To over-express	To introduce proliferation	[126]
12.	OCT-4 (pou5f1p-1), 0.4 kB, Chr-8q-24	To over-express	Increased of risk of CRC	[133]
13.	UCA-1, 1.4 kB/ 2.2 kB/ 2.7 kB, Chr-19p-13.12	To over-express	Induction of resistance to drug-induced apoptosis	[134]
14.	PRNCR-1, 13 kB, Chr-8p-24	To over-express	To increase cell proliferation	[135,136]
15.	LET, 2.3 kB, Chr-15q-24.1	To down-regulate	To induce metastasis	[137]
16.	Noncoding RAN, 2.3 kB, Chr-17q-25.1	To over-express	In the enhancement of cell invasion and migration	[138]
17.	PVT-1, Chr-8p-24.21	To over-express	To increase proliferation of cells and progression of the cell cycle. Also, induce anti-apoptotic activity.	[139,140]



First, the circulating intensities of transcripts of ncRNA along with alterations in post-transcription are not stable or are so variable that it is difficult to detect throughout unlike the disease stage. Secondly, there is no guileless standard assessment as well as consent to endogenous switch to quantify circulating ncRNAs. Thirdly, much of obtained outcomes have not been replicated &, besides, diagnoses of ncRNA-based appear as more precise in Asians as compared to those in Caucasian individuals [142]. In significance, actual outcomes need confirmation in manifold studies with the validation of larger scale across different populations and many centers. Also, their probable application as biomarkers, ncRNAs capacity of gene expression regulation generally as well as in gene networking included in transformation of tumor cell particularly, marking them extremely striking rehabilitation against the colorectal tumor. Though, several trials should be overwhelmed for the application clinically such as the absence of reliable delivery procedures and side effect determination. Consequently, novel effective & stable policies for editing of the genome, along with more effective & less poisonous delivery systems of gene therapy necessary to be established before the ncRNA may establish potential CRC treatment.

## **7. Gut Microbiome in CRC**

More than 100 trillion microbes the human body contains [143], dissimilar communities are existing in vast series of body positions, most of which are hosted in the gut. The most studied bacterial group is anaerobic bacteria because of their abundance, these residents are said to be microbiome comprising a huge microbes variety including, fungi, viruses, and archaea [144–146]. For maintaining body homeostasis such communities of microbes are indispensable and are birth acquired [147]. An enormous amount of environmental or genetic aspects, like drug intake, alcohol, and diet, geography as well as age control the interaction between microbiome and host that is dynamic. Ninety percent of endogenous nature bacteria are present, comprised of two predominant phyla named Bacteroidetes and Firmicutes. Normal colonic microbiome includes other members like Lactobacilli, Enterococci, Streptococci, Enterobacteriaceae, EU bacterium, Fusobacterium, or Bifidobacterium [148–150]. With the application of sequences of rRNA like traditional methods of culture, microbiome composition is studied chiefly [150–152]. In human physiology and metabolism microorganisms of the intestine serve a crucial function, with their tasks counting the intonation of the human system of immunity as well as colony prevention via enteropathogenic bacteria, essential vitamins synthesis such as vitamin K, and energy extraction from carbohydrates that are indigestible like pectin's [143,153–155]. Such bacteria of commensalism then yield the benefit of an exclusive milieu in return having a concentration of oxygen also having abundant nutrients and adequate pH range. Serious problems are caused by normal flora alterations that are not surprising instead of their vast importance. For example, the natural relation is disrupted among the intestinal microbiota and the host, the condition is known as dysbiosis, in inflammatory bowel disease (IBD), and CRC is thought to be among the most probable causes. In the development of dysbiosis, several aspects like some diet types or antibiotic treatment are said to be included [156–158].

### ***7.1 Dysbiosis and Colorectal Cancer: Breaking the Mutualism***

How colonic carcinogenesis could be induced by dysbiosis, inflammation of chronic seems a key mechanism, although not yet clear. Chronic inflammation causes several cancer types, this fact supports this hypothesis [159,160]. For example, colon cancer risk is augmented, linked by inflammatory bowel diseases (IBD)

[161,162]. Activation of the immune system has resulted from alteration in normal flora, so augmenting inflammation by which IBD is characterized is the first stage of this disease. In certain situations, dysbiosis is observable, as IBD individuals have a greater suffering probability of CRC [161,163,164], it is likely to assume that the previous dysbiosis stage drive IBD-related CRC. One of the main respondents responsible for the evolution of the onset of colonic carcinogenesis is the microbiome. The differences in microbial signature among CRC patients and healthy populations are based on this research field. Certainly, an enrichment in proinflammatory bacteria is revealed by next cohort methods of sequencing based on rRNA of 16s, such as protective bifidobacterial, lower the abundance of butyrate producers and *Fusobacterium*, that is overrepresented too in further disorders (like IBD) [165,166]. Proinflammatory bacteria may exacerbate, disturb or inhibit normal responses of the host causes inflammation, cell proliferation, and abnormal apoptosis. For CRC onsets, such as reactive oxygen intermediates which induce cell transmission and can damage host DNA and some kind of toxins, there is another proposed mechanism of the presence of secondary metabolites [167–171]. Whether a community of microbes, specific bacterium, or together both synergistically/sequentially cause CRC, however it remains unknown. Reduction in the risk of developing CRC contributed by a set of lifestyle changes which establishment is led by the results of these studies. Therefore, CRC-affected patients could reduce in number drastically, because of coordinated endocrinologists and oncologists' action. In this multiphase process, despite this, researchers engrossed in some microbiota associates as crucial disbelievers.

## **8. Microbiome and Diet: A Possible Link with CRC**

Colorectal cancer prevalence is increasingly growing in countries in Asia's east, East Europe, as well as the Mediterranean where it was historically unproblematic [172,173]. Dietary adjustments are largely to blame for such a pattern. While these areas used to eat massive amounts of fruits or veggies, the “modern dietary pattern,” which is defined by a large amount of fat or red meat, has subsequently changed to a more. However, as the prevalence of colorectal cancer rises, meat intake rises as well. Few pathways, such as heme iron, HCAs, Nitrosamines, and PAHs, have been suggested to clarify this relationship [174]. While, among the most intriguing results of meat that has been processed and heavy intake of red meat, that induces bacterial accumulation that is toxic, is a significant modification in the structure of microbiome in the gut [175]. When Ou and colleagues contrasted samples from black Americans and Africans from the countryside in their research, they discovered that dietary habits have a big impact on the structure of the microbiome [176]. While both classes were of the same race, their microbes were substantially distinct with *Bacteroidia* like *Bacteroidetes fragilis* prevailing in *Prevotella* and black Americans, In African samples, *Oscillopsia* or *Succinivibrio* feature prominently. As a result, their microbes were drastically distinct from *Bacteroidia* like *B. fragilis*. This disparity can be attributed to the reality that Black Americans intake more fat or red meat than Africans in rural areas. Feng or his colleagues brought this theory towards the next stage by comparing specimens from numerous dietary habits with Colorectal cancer [177]. They found that bacteria with larger ratios in colorectal cancer samples were present at reduced ranks in respondents who ate a lot of fruits and veggies (such as *Alistipes finegoldii*, *Parabacteroides merdae*, *Bilophila wadsworthia*, and *Bariatricus massiliensis*) However, using direct genetic analysis of genomes, they were more prevalent in customers who ate a lot of red meat. Reference [178] this fact could explain the higher incidence in response to a diet rich in fat, as the antitumor properties of butyrate are well established. Furthermore, the expression of the microbial genes, involved in the production of

secondary bile acids and deconjugation of bile acids, is higher when fat intake is high [178]. Due to their ability to induce oxidative stress, DNA damage, or mutation the secondary bile acids such as lithocholic acid are considered to be tumor-promoting agents. why a high fat intake leads to the onset of colon cancer these two factors could explain. Since butyrate's anticancer effects are well known, this reality may justify the increased occurrence concerning a high-fat diet. Besides that, when fat consumption is elevated, activation of microbial genes implicated in secondary bile acid synthesis and bile acid conjugation loss is greater. Secondary bile acids, like 3 $\alpha$ -hydroxy-5 $\beta$ -cholan-24-oic acid or LCA, are called cancer-promoting factors because of their capacity to cause oxidative damage, Damage to DNA, or alterations. Such two variables may clarify how a diet high in fat causes colon cancer to develop. This would, however, be the answer if the issue is one of diet. The analysis of O'Keefe found that a high-fiber diet leads to a higher intake of butyrate [178]. Fiber consumption can defend against colorectal cancer through microbial butyrate formation poly-associated with 4 commensal microbes or even less the maker of butyrate, according to a BALB/c(albino) inbred animal model. Donohoe or his colleagues created B fibrisolvens [179]. Such mice were provided similar and nutritionally balanced low- or high-fiber meals, as well as the animals, provided the higher amount of fiber developed the most butyrate, as anticipated. When mice colonized with *Butyrivibrio fibrisolvens* are provided a fiber-rich diet, they are least prone to cancer progression, demonstrating the defensive influence of butyrate in colorectal cancer once cancer-promoting factors are injected.

## **9. New Developments in colorectal cancer prognosis and Staging**

### ***9.1 Biomarkers in the Treatment of Colorectal cancer***

A biomarker, which is a biological agent, is used to assess the results of medication or the occurrence or development of a specific disorder. High sensitivity, safety, and specificity are important characteristics of biomarker, useful for facilitating treatment selection and establishing an accurate diagnosis Regarding being simple to calculate [180].

CpG island methylator phenotype (CIMP), microsatellite instability (MSI) and chromosomal instability (CIN), and microsatellite instability (MSI) are three major alterations found in CRC as noted previously. These alterations can therefore be used as biomarkers that can be identified in feces, tumor tissue samples or blood, and result in changes in proteins, genetic material, RNA, or metabolic compounds [181]. In comparison to the existing procedures (sigmoidoscopy, virtual colonoscopy, colposcopy, and fecal blood test (FOBT), double-contrast barium enema, molecular analyses are supposed to be much more accurate, responsive, and well accepted by patients. While more studies are required for their authentication. The most commonly used biomarkers in Colorectal cancer are generally the identification of microsatellite instability and KRAS variants in tumor specimens to determine the tumor, make a disease prognosis, and administer medication [181]. While other biomarkers tend to exhibit very low sensitivity, but high specificity is used for diagnosis, including the determination of CEA and FOBT [182]. Why effective molecules for Colorectal cancer quick detection are searched by researchers is the main reason. Using instruments, microRNA, CpG islands, and microarrays of genes were evaluated. and methylator phenotype which is observable in blood or stool is a very remarkable finding in this context. Many of these products(kits) have a promising future ahead of them and are currently

undergoing clinical trials. Given the limitations of current Colon cancer intrusiveness, poor accuracy and susceptibility, and increased prices of new, molecular genetic markers with diagnostic or prognostic importance, colon cancer is becoming a critical problem for improving anti-cancer therapies or patients' outcomes. Even so, there are some shortcomings in the assumptions. Over the last two decades, numerous molecular genetic markers were investigated, with promising results. First, since most research articles used a limited data set or were backdated evaluations of a single study, estimates lack precision and repeatability. Second, the data is insufficiently accurate for use in medical care in most instances, the data received lacks identification and sufficient verification. Analysis or interpretation thereby remains challenging. Moreover, the absence of standardized endogenous controls as well as a shortage of standardization strategy validate the obtained results and make it difficult. In consequence, in advanced CRC stages only the KRAS gene in response to EGFR-targeted therapies used as a predictive marker and has entered routine clinical practice despite the vast number of possible genetic markers, in addition to the diagnosis and prognosis of CRC, the application of genetic markers has a bright future in the advancement of specific and relevant treatment. Regardless of their real drawbacks, a great degree of attention is being spent on this topic.

### **9.2 Gene-Expression Profiling (GEP)**

GEP-based research evaluates the expression of genes in healthy and a sample of tumor tissue as well as specimens from various stages of the disorder [183]. These similarities are thought to provide valuable knowledge about the disease's initial diagnosis and the best care by each patient. Clinical Laboratory Improvement Amendments certified labs now offer a range of Gene expression profiling strategies, the form of evaluation used, or the set of genes studied differed among them Error! Reference source not found.. Given the growing number of Gene expression profiling assessments as available in recent years and its possible advantages in both clients (adjuvant treatments pain and risk factors are lowered) as well as community (Treatment costs are lower for clients who do not benefit from therapeutic compounds). According to the National Comprehensive Cancer Network (NCCN, 2015), there is also a piece of substantial information for any accessible multigene assessment to estimate the tangible benefit of chemotherapy. Furthermore, the National Comprehensive Cancer Network has decided that there is insufficient evidence to focus the drug therapy decisions on such evaluation, so more research in this area is required to assess their predictive and therapeutic feasibility.


## **10. CRC Treatment with Advanced Therapies**

Colorectal Cancer is being treated with an antitumor compound derived from medicinal plants.

### **10.1 Angelicin**

Angelicin, also known as 2-oxo-(2H)-furo (2,3-h)-1-benzopyran Figure 3, is a naturally occurring complex molecule isolated from *Angelica archangelica* (garden archangelica), a traditional Chinese herb. Angelicin has antitumor properties by preventing malignant action in various forms of cancer, like invasion, colony-forming, relocation, and propagation. Angelicin activates cytotoxic effects in a variety of cancerous and not cancerous


cells by genotoxicity. In colon cancer, angelicin increases cell toxicity by blocking HDAC8 and polymerization of tubulin function [184].



**Figure 3:** Structure of Angelicin

### 10.2 Garcinol

Garcinol Figure 4 is derived from *Garcinia Indica*, a purple mangosteen family member commonly known as kokum, and has long been lauded in the tropical regions. The biological properties of garcinol, on the other hand, are starting to appear. Garcinol and its compounds demonstrated strong GI activities on all intestinal cells following three days of therapy, with half-maximal inhibitory concentration values ranging from 3.2–21.4 microM. Garcinol prevents tumor cell proliferation more efficiently than regular immortal cells, according to research. Such findings indicate that Garcinol and its residues can inhibit the development of colon cancer cells while leaving healthy cells unchanged. Garcinol, on the other hand, triggers cell growth at small concentrations. Garcinol has functional epigenetic aspects linked with carcinogenesis through Hat’s inhibition of microRNA profiles or co-transcriptional modification of a protein. Garcinol's effectiveness in colon cancer has been demonstrated in a variety of in vivo studies [184].



**Figure 4:** Structure of Garcinol

## 11. CRC Treatments Currently Available

Based on characteristics of the tumor (e.g., presence or absence of biochemical markers, number and localization of metastases, progression of the tumor, and patient-related factors (For example, assessment, co-morbidity, and so on.) the A multimodal strategy is commonly used to determine the best first-line care for Colorectal cancer cases. The risk category is selected from a list of four choices to classify CRC patients that would be used to determine the course of treatment in practice:

Category 4: Sufferers with incurable cancer that do not receive comprehensive or sequential therapy: The aim of care in patients without any indications and a reduced probability of worsening would be to avoid tumor growth and extend therapy -free lifetime. As a cytotoxic drug, fluoropyrimidine drug paired, or not, with a biological focused product is the most widely used approach [185,186].

Category 3: Sufferers with unresectable, circulated tumors. The medication chosen with this patient group would be alleviating instead of therapeutic, with the primary aim of reducing signs, the disease's assertiveness, and development. As a consequence, the chosen 1st therapy should result in rapid metastatic progression. A cytotoxic doublet in combination with a managed agent is usually the best option to achieve a specific goal (anti-Vascular endothelial growth factor or anti-Epidermal growth factor receptor approaches). In oligometastatic cases that lead to medication, additional excision strategies may be needed to prolong the progression-free period. If excision procedures are not possible, the primary combination's decline as a preventive remedy should be investigated. In some situations, cancellation of all medications might be regarded [185,186].

Category 2: Sufferers with metastases that could be rejectable. Induction chemotherapy is used to minimize the amount and volume of metastases in such cases, enabling surgical removal later. In Kirsten rat sarcoma viral oncogene homolog WT tumors, cytotoxic dual and triplet cancer treatment is advised, which can be coupled with anti-Vascular endothelial growth factor or anti-epidermal growth factor receptor approaches. [185,186].

Category 1: Sufferers without any metastasis's absence of weak prognostic symptoms and liver or lung metastases (for example relapse during drug medication). In this situation, surgical removal of metastatic disease is the preferred procedure. Chemotherapy cannot be shown to increase optimal longevity in this population. Many CRC patients with metastatic cancer are handled with a mixture of selective biological weapons and toxic metabolites, as discussed previously. Sufferers with strong functional organs will be given second-line chemotherapy, which will be chosen as stated by a refractory-based administration. Patients that are resistant to Camptosar will be treated with a formulation containing oxaliplatin like FOLFOX and CAPOX as second-line therapy. Patients who are resistant to FOLFOX or capecitabine and oxaliplatin will undergo Camptosar monotherapy and FOLFIRI [217]. Fluoropyrimidines (for example 5-fluorouracil (5-FU) or Xeloda) are used as a first-line medication for preventative reasons, either alone or in conjunction with Folinic acid and other toxic metabolites. As an example, capecitabine/LV/oxaliplatin (CAPOX) or irinotecan (5-FU/LV/irinotecan (FOLFIRI) and oxaliplatin (5-fluorouracil/leucovorin/oxaliplatin (FOLFOX)). The use of Folinic acid reduces the treatment's toxicity. Although toxic effects of treatment are also intensified [185,217].

**Table 3: Biomarkers in Cancer**

Molecular Type	Marker	Biomarker	Cancer Contribution	Use of Predictive Analytics	Samples Used for the Test	Status	References
DNA		microsatellite instability (MSI). MSI tumors are described as dysfunctional loci with a board of mononucleotide markers (Bat-25, Bat-26, NR-21, NR-24, MONO-27).	Changes in frequently replicated sequences of DNA occur.	The prognosis for Microsatellite instability (MSI) tumors: vigorously, better: low, medication: failure to respond to Fluorouracil, Camptosar has a great response.	Tumor-based samples	In use	[223]
-		NRAS (neuroblastoma RAS viral oncogene homolog) and KRAS (Kirsten's rat sarcoma viral oncogene homolog),	Activation of the epidermal growth factor receptor signaling pathway facilitates replication.	If infected, the prognosis is weak, with a low chance of survival (codon twelve or thirteen). Medication: EGFR reaction is minimal.	Tumor-based samples, stool	In use for tumor-based samples and under evaluation for stool	[226]
		BRAF (v-RAF murine sarcoma viral oncogene homolog B1)	Activation of the EGFR signaling pathway facilitates propagation.	If infected: Colorectal cancer is classified as sporadic. Diagnosis: bad, Medication: EGFR-targeted treatment has had minimal response.	Tumor-based samples	In use	[190,193,194]
		Vimentin methylation is an example of a CIMP	Colon cancer tumorigenesis is caused by the Regulation of transcription	BRAF variations are possible., Colorectal cancer classification in CpG island methylator phenotype	Tumor-based samples, stool, blood samples	Under evaluation in tumor samples and use for stool	[195]
		Circulating free DNA (cfDNA)	Aprotic cell death	observing or Diagnosis	Blood sample	Under evaluation	[196]

RNA		Ribonucleic acid gene boards or microarrays of gene	Unidentified	Evaluation of the probability of relapse after a CRC evaluation	Tumor-based samples, stool, blood	Clinical validation	[197,198]
		table of microRNA biomarkers (miR-21, miR-106a, etc.)	Unidentified	Identification and prediction	Tumor-based samples, stool, blood	Clinical validation	[199]
		Biomarker panel for epidermal growth factor (EGF) receptor ligands (Solute Carrier Family 26 Member 3, AREG, epiregulin and Dual Specificity Phosphatase 6.)	Activation of the EGFR signaling pathway facilitates propagation.	Epidermal growth factor receptor-targeted treatment reaction	Tumor-based samples	Under evaluation	[200,201]
Protein		Determination of tumor-specific proteins. (carcinoembryonic antigen, Calprotectin, DAF, cancer antigen 19-9, etc.)	Unidentified	identification, prediction, observing	Stool, blood	Clinical validation	[202,203]
Others		cancer cells, DNA& RNA, and proteins circulate	Unidentified	observing or Diagnosis	Blood	Clinical validation	[240]

With three different options being available Chemotherapy treatment period is determined by the following factors:

- treatment until toxicity or progression,
- 3 to 6 months of continuous medication
- a prescription for induction accompanied by medication for maintenance [185].

In contrast to standard chemotherapy, Metastatic Colorectal Cancer proteins or manmade antibodies towards epidermal growth receptor (EGFR) or vascular endothelial growth factor (VEGF) were shown to increase the result. The most widely utilized Anti-vascular endothelial growth factor therapy strategies are Aflibercept, a recombinant fusion antibody, which inhibits VEGF-A, Vascular endothelial growth factor B, and PGF and manmade antibody Avastin, which attacks circulating Vascular endothelial growth factor-A. They are the first-line therapy for nearly all Colorectal cancer patients. When combined with cytotoxic agents. Anti-EGFR (epidermal growth factor receptor) therapy may only be utilized due to the lack of Kirsten’s rat sarcoma viral oncogene homolog mutations, whether as a sole agent or in conjunction with cytotoxic agents. The most effective anti-EGFR (epidermal growth factor receptor) drugs are monoclonal antibodies like Panitumumab or Cetuximab [185]. Aside from traditional chemotherapy, possible treatments have been investigated to minimize adverse effects, reducing the incidence of secondary tumors, and increasing treatment effectiveness. The use of probiotics, gold-based drugs, agarose tumor macro beads, and anti-inflammatory drugs are the very significant areas of research being pursued.

**Table 4:** Latest GEP (gene-expressing profiling) for CRC

Name of Assay	The Used DNA Markers	Test Type	References
Relative risk determination of colorectal cancer	TNF Alpha Induced Protein 6, CLECD4, Proline-Rich and Gla Domain 4, Vanin 1, Lamin B1, IL2RB, Annexin A3 are some of the genes that have been identified.	qRT-PCR	[207,208]
Following surgery estimation of colorectal cancer in individuals having stage II.	seven genes linked to the repetition of Colorectal cancer (Ki-67, Familial adenomatous polyposis, BGN, MYBL2, C-MYC, Inhibin Subunit Beta A, Growth Arrest and DNA Damage Inducible Beta.),) or Five reference genes ATP5E, Phosphoglycerate kinase 1, Ubiquitin B, Voltage-Dependent Anion Channel 2, Glutathione peroxidase 1)	qRT-PCR	[209,210]
Individuals having colon cancer with stage II & III in them a risk of reappearance of disease determination.	CA438802, Pyridine nucleotide-disulphide oxidoreductase domain 1, EDEM1, IL2RB, Zinc Finger Protein 697, THNSL2, SLC6A11, Interleukin-2 receptor alpha chain, Cytoplasmic FMR1 Interacting Protein 2, PIM3, Leukemia inhibitory factor, PLIN3, HSD3B1, Zinc Finger BED-Type Containing 4, PPARA, IL2RB	Microarray	[211,212]
Within five years the risk of reappearance of colorectal cancer.	KITLG, Fibroblast Growth Factor 1, ISG15, Oxidoreductase NAD Binding Domain Containing 1, PPP2CA, Tumor Protein P53 Inducible Nuclear Protein 1, ARHGAP18, Bestrophin 1, FKBP5, (Lysosomal Associated Membrane Protein 3, MRPS31, Nucleoplasmin 3, ABCC3, PRKACB	Microarray	[213]
Within five years the risk of reappearance of colorectal cancer.	-	634-transcript DNA microarray-based gene signature	[214]
Individuals having rectal cancer with stage I & individuals having colon cancer with stage I or II have a risk of reappearance of cancer.	Ribosomal Protein S10, BMI1, ETV6, H3F3B	qRT-PCR	[215]
Prediction of individuals having a risk of reappearance of cancer very low.	GCC messenger RNA quantitative analysis	qRT-PCR	[216]

### 11.1 Agarose Macro beads



An exponential curve that has been decreased reaches an asymptote or reduces as it gets bigger is the Gompertzian curve followed by organs and tumor growth. Towards Regulatory restrictions on growth that are either positive or negative tumors like organs susceptible as suggested by this evidence [218].

The positive control of tumor development is well known, according to a wide body of findings in the research. “compensatory hyperplasia” causes Tumor development is often triggered by incomplete surgical extraction of a tumor [219]. Bio signals that indicate the existence of a tumor mass even if that clump of cells is absent often slow or stop tumor growth [219]. This hypothesis is based on the utilization of hydrophilic agarose macro beads cell culture for CRC outgrowth. An interior space that can be used to contain tumor cells. created by two concentric layers of agarose constituted by agarose macro beads [227,228].

RENCA cells (a cell line from a Renal cortical adenoma in mice) were chosen in general. After being enveloped in macro agarose beads, numerous cancer cell lines also can establish colonies. Colonies of one cell are formed by such cells. containing several hundreds of cells that grow to the size of colonies after encapsulation. Around 6 to 24 months after encapsulation, As the colonies enlarge their development decreases before they reach a manageable scale. As an encapsulation of cell experience, a transformation procedure at least 2 subgroups of cells are chosen to generate cancer colonies throughout that period. Both *in vivo* production of not-encapsulated tumor cells is inhibited by the tumor inhibitory molecules whose production is induced by a growth-restrictive agarose environment. Proteins are among them, Gelsolin (GSN), Prosaposin (PSAP), peroxiredoxin 1 (PRDX1), secreted protein acidic and rich in cysteine (SPARC), phosphatidyl ethanolamine-binding protein (PEBP1), nucleoli (NCL), pigment epithelium-derived factor (PEDF), Fibulin (FBLN1), Serpine1 (Serbp1). Each of these secretory proteins, that eventually wind up lengthening the cell-cycle period of revealed cancerous cells, are thought to be the cause. Though its process of RENCA macro beads' inhibitory effect is unknown, multiple signals are produced. RENCA macro beads decrease the mitosis number and lengthen the period of S-phase as demonstrated by the results of different experiments in particular. This regulatory framework can be used to treat a variety of tumor derived from epithelial cells from various cell lines or species as RENCA macro beads have a indefinite mode of activity [220].

RENCA (commune of chile) micro-beads were tested in developed carcinoma in a stage 2/3 clinical experiment. Patients tolerate RENCA macro-beads well in general. Anorexia and fatigue Some of the most frequent side effects last anywhere from a few days to 3 weeks. Peripheral edema, abdominal distension, ascites, fluid deposition in the vicinity of the MBs, dyspnea, vomiting, nausea, pyrexia, constipation, abdominal pain is another less common adverse effect. Patients' positive responses to treatment include a decrease in targeted therapies, tumor stability, pain relief, as well as an increase in the standard of living [221]. The treatment's prospects are optimistic, as a phase 2/3 clinical study is presently in progress.

### ***11.2 Anti-Inflammatory Drugs***

#### **Anti-Inflammatory Medication**

Immune system cells and their components chemokines or cytokines), reactive oxygen species or reactive nitrogen species, and also some AA (polyunsaturated omega -6 fatty acid) derivatives, are all released primarily through the (cyclooxygenase (COX) and lipoxygenase (LOX) pathways.) Arachidonate cascade, cause long-term inflammation, which is a common characteristic of colon cancer. Tumor formation, propagation, penetration, and tolerance are all aided by this inflammatory reaction [222].

Anti-inflammatory medications are now useful in the prevention and diagnosis of colorectal cancer, as inflammation is now recognized as a factor in the disease's development and progression. . Non-steroidal anti-inflammatory drugs (Acetaminophen) block the synthesis of AA or ARA derivatives by suppressing cyclooxygenase enzymes, which are used in the majority of anti-inflammatory medicines. Aspirin, for instance, has shown promising results in the diagnosis of Colorectal tumors, minimizing the threat by up around half Sulindac, an NSAID it's been shown to minimize colon cancer inflammation, is another illustration of a non-steroidal anti-inflammatory used in Colorectal cancer -related inflammation. Sulindac in conjunction with Lipitor has also been shown to delay cancer growth [223].

NSAIDs have toxicities like stomach ulcers and kidney problems, despite their anti-inflammatory effects [224], As a result, they are mainly used to avoid Colorectal cancer. Twenty-one of thirty-nine in increased patients, like those with inflammatory bowel syndrome, UC, and Familial adenomatous polyposis, instead of treating it. To prevent these adverse reactions, a new class of nonsteroidal anti-inflammatory drugs called COXibs has also been created to diagnose and control CRC [225].

A few of these drugs, like rofecoxib (Cox-2 selective nonsteroidal anti-inflammatory drug (NSA) which had been withdrawn from the marketplace in 2004, can cause cardiovascular exposure even though they do not influence the digestive system [226].

Celecoxib is the most effective drug in this class of Cox-2 inhibitor since it has been shown to avoid colon cancer and reduce tumors, even in late stages. besides, Celecoxib also has no gastrointestinal side effects or not causes cardiovascular complications [227] or not causes cardiovascular complications [228]. New formulations are also being tested to reduce the known aftereffect. As an example, Celecoxib microbeads, are a type of new drug that only attacks intestinal cells. In vitro experiments are presently has been used to evaluate this formula, with animal tests anticipated in the coming years [239]. Celecoxib is also being combined with curcumin(turmeric), a *Curcuma longa* product, to produce a symbiotic antitumor impact.) [229].

### ***11.3 Probiotics***

Given the function of microbiota throughout the initiation or maintenance of CRC, it is rational to assume whether it can be shifted to a "non-malignant " microbiome, thus preventing the tumorigenic phase. Probiotics, in this manner, are a possible therapy for Colorectal cancer, as well as a preventative measure, which can be used as a drug to other therapies.

Probiotics are active microbes that, if given in sufficient quantities, provide health benefits to the recipient. LAB, such as *Lactobacillus*, *Leucon Stoc*, *Bifidobacterium*, *Enterococcus*, *Streptococcus*, or *Lactococcus*, have

been extensively investigated for the treatment of CRC. Reference [230] conducted a study to connect yogurt intake with colorectal cancer risk, including forty-five, two forty-one active participants whose food choices, as well as other behavioral factors, are meticulously examined. When other lifestyle variables were taken into account, such as whether yogurt was consumed alone or in conjunction with those other milk products, these researchers discovered that consuming yogurt was related to a low probability of CRC. Given the challenge of dealing with human organisms, studies into Probiotics' mode of activity have largely relied on clinical trials.

For instance, Chen or colleagues [231] explored the influence of oral administration of *Lactobacillus* in an animal model of colon cancer and discovered that such bacteria could minimize the severity of disease by apoptotic cell death induction. Choi or colleagues discovered that soluble polycarbohydrates could be involved throughout this ability to induce cell damage [232].

As a result, Sah or colleagues [233] showed that certain probiotics found in yogurt may generate antioxidant proteins with activities that scavenge free radicals, In the lumina, there is oxidative damage implying which they often minimize, just as result, slow and stop the development of colorectal cancer. Probiotic strains are important in the prevention of colon cancer because of their antioxidant properties and ability to increase apoptosis.

#### ***11.4 Functional Foods***

As a result of metabolic pathways, oxygen radicals called O<sub>2</sub> molecules that have one or more incomplete or not paired electrons. Reactive oxygen species perform a biological function in microbe defense, mitogenic reaction, and various molecular processes at small concentrations [234,235]. Even so, an overabundance of such chemical compounds, that can be triggered by air degradation, tobacco or drug utilization, as well as other stressful events, can damage cell structures by oxidizing fatty acids, Deoxyribonucleic acid, or proteins [236]. These circumstances are being linked to a variety of human disorders, including arthritis and tumors [237].

As a result, preserving and restoring redox equilibrium is essential for the entire organism to function properly, making the redox or antioxidant method some of its key development proposals in food supplements technology [238,239]. Antioxidants derived from organic resources have arisen with a modern technique for cell protection from oxidative stress in the body in this case.

Other very ample specialized metabolites present in plants are polyphenol, grain, and lentils (cereal grains, corn, dry fruits, common oat, great millet, wheat, peas, & legumes), oilseeds (oilseed rape, canola, linseed, and olive seeds), fresh fruit and veggies and mixed drinks (fizzy, caffeine, and alcoholic drinks) all contain phenolic compounds [240].

Polyphenolic compounds, also known as polyphenols, are a diverse group of compounds that include polyphenols, water-soluble vacuolar pigments, and flavonoids [241]. In response to their anticancer properties, each of these polyphenolic substances have a high antioxidant capacity, thus lowering cancer risk [242].

In addition to triggering cell arresting or apoptotic cell death and enzyme detoxification, numerous polyphenolic substances have been appeared to have chemopreventive, anti-tumor, antioxidant activity, and Behavior that is estrogenic or antiestrogenic. They've also been linked to alterations in signal transduction and the immune response of the host, many polyphenolic substances and numerous botanical extracts, in specific, have been appeared to have anti-cancer properties in some models of cancer [243,244].

## **12. Colorectal cancer medicines that are dependent on metals**

Metals have been used in medicinal objectives since prehistoric days. powder of Cinnabar, a mercury derivative, was, for instance, commonly used in contemporary Indian and Chinese medicines [245] Topical balms containing silver sulfadiazine(sulfonamide) are widely used to treat wounds. TMXK Tablet, which contains CrPic3 as its primary component, is being used in China to diagnose adult-onset diabetes [246].

The finding of  $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$ , on the other hand, is among the most significant accomplishments of inorganic chemistry in science. And in the 1960s, the antitumor characteristics of cisplatin also called cisplatinum [247], were found by chance. Many more metal-organic compounds have been designed to treat tumors ever since [248–251]. The most promising candidates, Pt and Au, will be discussed in this article, as well as their use in CRC chemotherapy.

### **12.1 Pt**

$[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$  was the first metal to be used in cancer-killing. This formulation is efficient against such a variety of cancers, comprising testicular, and strong tumor of neck and head and cancer of ovary [247–252]. Its growth is attributed to its mode of activity:

Cisplatin can stick deoxyribonucleic acid and cause apoptotic cell death as a result.  $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$  reaction with Deoxyribonucleic acid at the N7 location of the main loop-hole guanines, Inside the cell, this is the highly uncovered and nucleophilic location. Consequently, these crosslinks of inter/intra, several polyadducts which are polyfunctional can produce an association with DNA along with  $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$ . Despite its effectiveness,  $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$  has severe side effects as a consequence of its working principle. Kidney failure, as well as deafness, are the most common aftereffects. The concentration of  $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$  in the kidney's proximal tubule causes neurotoxic effects [253,254]. Ototoxicity, on the other hand, is caused by the death of sensory cells of the auditory system as a consequence of an increase in ROS [253–255]. In particular, there has been a rise in tumor response to cisplatin treatment.

The most common emergence of action is an enhancement in the recovery of DNA cisplatin adducts. Other options include an increment in cytosolic drug inhibition and a decrease in medication intake [256,257]. Various agonists, including Eloxatin and carboplatin, have been developed to sustain the effectiveness of cisplatin while avoiding its drawbacks. As a result, oxaliplatin is among the most commonly used drugs in the treatment of CRC. The significance of oxaliplatin, also known as trans-L-diaminocyclohexaneoxalatoplatinum, stems from the fact that it has no cross-resistance to  $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$ , enabling to use it when cancer has developed resistance to that medication. Imbalance in a variety of proteins, that accept every adduct type, can create this

lack of cross-resistance as well as the different side effects they have[258]. The fact that [Pt (NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] does not cause ototoxicity or toxicity in the kidneys is even more extraordinary FOLFOX [259] is a chemotherapy regimen that includes [Pt (NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] and in fusional 5-FU/LV. FOLFOX has significantly increased the success rate: 5-FU therapy results in a 20percent of overall return rate, which rises to 50percent when paired with [Pt (NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] [260]. In carcinoma patients, the therapy of 5-FU and [Pt (NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] also improves survival [260].

### **12.2 Au (Gold)**

Over the last few years, some metal-based chemotherapeutic agents comprising Au(I) and Au (III) have been developed. The compositions of these formulations, on the other hand, vary significantly because the gold molecules can be coupled to porphyrins, PH<sub>3</sub>, dithiocarbonates, or carbene ligands, increase antitumor activity and other characteristics [250,261–263].

Auranofin is one of the most well-known Au-containing antitumor medications[2,3,4,6-Tetra-o-acetyl-1-thio-D-glycopyranosato (triethyl phosphine) gold] Known as Au(I) substance with ligands of phosphine and thiol that has been reported in the alleviating or preventing rheumatism medication in the past [261]. Auranofin works by inhibiting TR/TrxR, which leads to a rise in ROS, which causes an imbalance between free radicals and antioxidants in your body and eventually activates signaling pathways that initiate apoptosis. As a consequence, auranofin can stimulate apoptotic cell death in cancer cells that are susceptible to [Pt (NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] [264]. Certain Au-containing drugs can trigger cell death in tumor cells because the Au atom in auranofin is essential for TrxRs inhibition [265–267].

Gold atoms are highly linked to thiol and selenic groups, allowing them to join selenium-dependent proteins like TrxRs, which are activated in some tumors, including CRC, and are directly involved in cancer development and mortality [268], implying that inhibiting it causes tumor cell death [269]. Certain Au containing drugs can trigger cell death in tumor cells because the Au atom in auranofin is essential for TrxRs inhibition [270] which is important for colorectal cancer cell (homeostasis) self-regulating process by which biological systems tend to maintain stability while adjusting to conditions that are optimal for survival [271]. This sensitivity extends to all Au-containing substances once more. Instead of impacting nucleic acids, gold(I) compounds interrupt the oxidation-reduction reaction by increasing reactive oxygen species levels within the cell and changing the mitochondrial function, which activates the cell death pathway and causes regulated cell death [272–277].

### **13. Prospects for the future and Analysis**

Colorectal cancer has now become a worldwide general populace wellness concern because of its extreme prevalence as well as the death rate. To empower researchers and practitioners with just an upgraded perspective of the useful observations into this disorder, we have examined the most recent findings in Colorectal cancer research, and also the most recent findings in testing and therapy techniques. A combination of inherited and external variables causes CRC. which must be studied to develop new preventive initiatives of the most crucial lines of defense against the disease's rising incidence.

The main colorectal cancer genes were identified in the last century, and their infectious agents' variations were related to an elevated threat of colon cancer. Furthermore, research into their genetic patterns resulted in the development of Inheritable CRC diseases, that has been identified, and also unique risk assessment initiatives and genetic testing that patients and their relatives can use to lower their risk of developing the disease. Nevertheless, colorectal cancer familial aggregation may occur outside of well-defined colorectal cancer family syndromes; as a result, various epidemic studies are being conducted to identify polymorphisms explaining resistance to Colorectal cancer in various populations. The findings of such investigations could lay the basis for a new wave of genetic diagnostic tests. Even though many of the significant cancer genes implicated in colorectal cancer have been identified, the impact of additional external influences on this disease is unknown. In this framework, a more thorough investigation of the link between food, microbiome, and Colorectal cancer is required. The findings of the research may bring the development of a series of life modifications that help to reduce the threat of colorectal cancer. Furthermore, when the consistency of the ecological communities of commensal, symbiotic, and pathogenic microorganisms appear to affect the progression of Colorectal cancer adjuvant treatments focused on probiotics or prebiotics are being investigated to increase the reaction to conventional chemotherapy drugs and to decrease the amount and intensity of medication administration, resulting in a better patient outcome. Likewise, shortly, the design and deployment of new accurate and selective biological markers would enhance therapeutic approaches, as a result, doctors will be able to identify CRC patients in the phase of the disease, improving the diagnosis of thousands of individuals. Just the detection of Microsatellite instability and Kristen's rat sarcoma viral oncogene homolog mutations in tumor specimens is presently used for testing and therapy administration.

Various experiments focused on CpG island methylation, DNA microarrays, and micro-RNA expression morphology are being evaluated for initial CRC detection and while they have a promising future, they will need to be validated in huge populations. Precision medicine is quickly have become an essential tool in the treatment of patients. As a result, to identify the most suitable therapy, an in-depth evaluation of every victim's tumor features is needed.

Ultimately, most of today's Colorectal cancer research is devoted to the advancement of potential treatments which are less violent and more beneficial than current therapies. And in the future, advances in this field and the therapeutic potential may increase the ultimate viability or wellbeing life of colorectal cancer cases. Very current evidence from the HINTS indicates that CRC test usage is lower than rates for many other suggested tumor diagnostic measures in comparison to past studies utilizing nationwide data (10, 16, 26). We should explore differences between the sexes in each of these occurrences and causes or determinants of test usage since CRC is the 1st tumor for that we have a prescribed medical test in both men and women. Our results point to new directions for future research into gender disparities. Sexual identity intervention methods or communications, if validated in future research could increase colon cancer testing levels. Colorectal cancer prevalence and death patterns and trends are related to current stages of human growth, and the gradual improvements may indicate the acceptance of the further modern way of living. To minimize the percentage of cases with Colorectal cancer in the upcoming years, resource-dependent strategies, such as early detection in low-lying areas supported by timely identification in high-density areas, will be required. Patterns and

inclinations in occurrence and death rate due to colorectal cancer may be the reflection of adaptation of western lifestyle as there seen incremental changes in current development levels of human.

The number of colorectal cancer patients is needed to reduce in future decades together with low-income prevention and high-income settings detection as involvements depend upon targeted resources. MEDLINE and manual searches are the electronic searches used to identify relevant articles of reference lists.

#### **14. Conclusion**

Colorectal cancer has now become a worldwide public health concern due to its high prevalence and mortality rate. To empower researchers and practitioners with just an upgraded perspective of the useful observations into this disorder, we have examined the most recent findings in Colorectal cancer research, and the most recent findings in testing and therapy techniques.

The findings of such investigations could pave the way for a new era of genetic diagnostic tests. Likewise, shortly, the design and deployment of new accurate and selective biological markers would enhance therapeutic approaches, as a result, doctors will be able to identify CRC patients in the phase of the disease, improving the diagnosis of thousands of individuals. Ultimately, most of today's Colorectal cancer research is devoted to the advancement of potential treatments which are less violent and more beneficial than current therapies. And in the future, advances in this field and their therapeutic potential will increase the ultimate survival and well-being of life of colorectal cancer patients.

#### **Acknowledgment**

We would like to thank Allah Almighty, our parents, and our teachers for their support and blessings.

#### **15. Conflicts of Interest**

The authors declare no conflict of interest.

#### **References**

- [1]. M. M. Center, A. Jemal, R. A. Smith, and E. Ward, "Worldwide Variations in Colorectal Cancer," *CA. Cancer J. Clin.*, vol. 59, no. 6, pp. 366–378, Nov. 2009, doi: 10.3322/caac.20038.
- [2]. C. Bosetti et al., "Trends in cancer mortality in Mexico, 1981-2007," *Eur. J. Cancer Prev.*, vol. 20, no. 5, pp. 355–363, Sep. 2011, doi: 10.1097/CEJ.0b013e32834653c9.
- [3]. B. Stewart, C. P. Wild, and (Eds), "IARC Publications Website - World Cancer Report 2014." 2014, Accessed: Mar. 22, 2021. [Online]. Available: <https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014>.
- [4]. M. M. Center, A. Jemal, and E. Ward, "International trends in colorectal cancer incidence rates," *Cancer Epidemiol. Biomarkers Prev.*, vol. 18, no. 6, pp. 1688–1694, Jun. 2009, doi: 10.1158/1055-9965.EPI-09-0090.

- [5]. C. C. Murphy, L. C. Harlan, J. L. Lund, C. F. Lynch, and A. M. Geiger, "Patterns of Colorectal Cancer Care in the United States: 1990-2010," *J. Natl. Cancer Inst.*, vol. 107, no. 10, p. 198, Oct. 2015, doi: 10.1093/jnci/djv198.
- [6]. B. F. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, "IARC Publications Website - GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0," 2012. Accessed: Mar. 22, 2021. [Online]. Available: <https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012>.
- [7]. C. Fitzmaurice et al., "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden," *JAMA Oncology*, vol. 3, no. 4. American Medical Association, pp. 524–548, Apr. 01, 2017, doi: 10.1001/jamaoncol.2016.5688.
- [8]. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012," *CA. Cancer J. Clin.*, vol. 65, no. 2, pp. 87–108, Mar. 2015, doi: 10.3322/caac.21262.
- [9]. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," *CA. Cancer J. Clin.*, vol. 61, no. 2, pp. 69–90, Mar. 2011, doi: 10.3322/caac.20107.
- [10]. H. Wang et al., "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015," *Lancet*, vol. 388, no. 10053, pp. 1459–1544, Oct. 2016, doi: 10.1016/S0140-6736(16)31012-1.
- [11]. O. Kronborg, "Population Screening for Colorectal Cancer, the Goals and Means," *Ann. Med.*, vol. 23, no. 4, pp. 373–379, Jan. 1991, doi: 10.3109/07853899109148076.
- [12]. D. M. Davis, J. E. Marcet, J. C. Frattini, A. D. Prather, J. J. L. Mateka, and V. N. Nfonam, "Is it time to lower the recommended screening age for colorectal cancer?," *J. Am. Coll. Surg.*, vol. 213, no. 3, pp. 352–361, Sep. 2011, doi: 10.1016/j.jamcollsurg.2011.04.033.
- [13]. M. M. Center, A. Jemal, R. A. Smith, and E. Ward, "Worldwide variations in colorectal cancer," *Diseases of the Colon and Rectum*, vol. 53, no. 7. Wiley-Blackwell, p. 1099, Jul. 01, 2010, doi: 10.1007/DCR.0b013e3181d60a51.
- [14]. A. Hadjipetrou, D. Anyfantakis, C. G. Galanakis, M. Kastanakis, and S. Kastanakis, "Colorectal cancer, screening and primary care: A mini literature review," *World Journal of Gastroenterology*, vol. 23, no. 33. Baishideng Publishing Group Co., Limited, pp. 6049–6058, Sep. 07, 2017, doi: 10.3748/wjg.v23.i33.6049.
- [15]. H. Yamagishi, H. Kuroda, Y. Imai, and H. Hiraishi, "Molecular pathogenesis of sporadic colorectal cancers," *Chinese Journal of Cancer*, vol. 35, no. 1. Landes Bioscience, p. 4, Jan. 06, 2016, doi: 10.1186/s40880-015-0066-y.
- [16]. A. I. Robles et al., "Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers," *Gastroenterology*, vol. 150, no. 4, pp. 931–943, Apr. 2016, doi: 10.1053/j.gastro.2015.12.036.
- [17]. M. J. Schell et al., "A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC," *Nat. Commun.*, vol. 7, no. 1, pp. 1–12, Jun. 2016, doi: 10.1038/ncomms11743.



- [18].A. kumar Pandurangan, T. Divya, K. Kumar, V. Dineshababu, B. Velavan, and G. Sudhandiran, "Colorectal carcinogenesis: Insights into the cell death and signal transduction pathways: A review," *World Journal of Gastrointestinal Oncology*, vol. 10, no. 9. Baishideng Publishing Group Co, pp. 244–259, Sep. 01, 2018, doi: 10.4251/wjgo.v10.i9.244.
- [19].E. R. Fearon, "Molecular genetics of colorectal cancer," *Annu. Rev. Pathol. Mech. Dis.*, vol. 6, no. 1, pp. 479–507, Feb. 2011, doi: 10.1146/annurev-pathol-011110-130235.
- [20].E. M. Stoffel and F. Kastrinos, "Familial colorectal cancer, beyond lynch syndrome," *Clin. Gastroenterol. Hepatol.*, vol. 12, no. 7, pp. 1059–1068, Jul. 2014, doi: 10.1016/j.cgh.2013.08.015.
- [21].R. A. Kerber, D. W. Neklason, W. S. Samowitz, and R. W. Burt, "Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch Syndrome) in a large population database," *Fam. Cancer*, vol. 4, no. 3, pp. 239–244, Sep. 2005, doi: 10.1007/s10689-005-0657-x.
- [22].S. I. Grivennikov et al., "Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth," *Nature*, vol. 491, no. 7423, pp. 254–258, Nov. 2012, doi: 10.1038/nature11465.
- [23].K. Wang et al., "Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis," *Immunity*, vol. 41, no. 6, pp. 1052–1063, Dec. 2014, doi: 10.1016/j.immuni.2014.11.009.
- [24].O. Dmitrieva-Posocco et al., "Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer," *Immunity*, vol. 50, no. 1, pp. 166–180.e7, Jan. 2019, doi: 10.1016/j.immuni.2018.11.015.
- [25].F. R. Greten and S. I. Grivennikov, "Inflammation and Cancer: Triggers, Mechanisms, and Consequences," *Immunity*, vol. 51, no. 1. Cell Press, pp. 27–41, Jul. 16, 2019, doi: 10.1016/j.immuni.2019.06.025.
- [26].P. K. Ziegler et al., "Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis," *Cell*, vol. 174, no. 1, pp. 88–101.e16, Jun. 2018, doi: 10.1016/j.cell.2018.05.028.
- [27].R. S. Goldszmid, A. Dzutsev, S. Viaud, L. Zitvogel, N. P. Restifo, and G. Trinchieri, "Microbiota modulation of myeloid cells in cancer therapy," *Cancer Immunol. Res.*, vol. 3, no. 2, pp. 103–109, Feb. 2015, doi: 10.1158/2326-6066.CIR-14-0225.
- [28].Y. Zhen, C. Luo, and H. Zhang, "Early detection of ulcerative colitis-associated colorectal cancer," *Gastroenterology Report*, vol. 6, no. 2. Oxford University Press, pp. 83–92, May 01, 2018, doi: 10.1093/gastro/goy010.
- [29].J. Terzić, S. Grivennikov, E. Karin, and M. Karin, "Inflammation and Colon Cancer," *Gastroenterology*, vol. 138, no. 6, pp. 2101–2114.e5, May 2010, doi: 10.1053/j.gastro.2010.01.058.
- [30].B. Khor, A. Gardet, and R. J. Xavier, "Genetics and pathogenesis of inflammatory bowel disease," *Nature*, vol. 474, no. 7351. Nature Publishing Group, pp. 307–317, Jun. 16, 2011, doi: 10.1038/nature10209.
- [31].H. Shaked et al., "Chronic epithelial NF- $\kappa$ B activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 109, no. 35, pp. 14007–14012, Aug. 2012, doi: 10.1073/pnas.1211509109.

- [32].C. P. Wild and B. . Stewart, "World Cancer Report 2014," 2014. Accessed: Mar. 22, 2021. [Online]. Available: [https://www.who.int/cancer/publications/WRC\\_2014/en/](https://www.who.int/cancer/publications/WRC_2014/en/).
- [33].H. Brody, "Colorectal cancer," *Nature*, vol. 521, no. 7551. Nature Publishing Group, p. S1, May 14, 2015, doi: 10.1038/521S1a.
- [34].D. Cunningham et al., "Colorectal cancer," *The Lancet*, vol. 375, no. 9719. Elsevier, pp. 1030–1047, Mar. 20, 2010, doi: 10.1016/S0140-6736(10)60353-4.
- [35].E. R. Fearon and B. Vogelstein, "A genetic model for colorectal tumorigenesis," *Cell*, vol. 61, no. 5. Elsevier, pp. 759–767, Jun. 01, 1990, doi: 10.1016/0092-8674(90)90186-I.
- [36].H. T. Lynch and A. de la Chapelle, "Hereditary Colorectal Cancer," *N. Engl. J. Med.*, vol. 348, no. 10, pp. 919–932, Mar. 2003, doi: 10.1056/NEJMra012242.
- [37].A. Umar et al., "Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability," *J. Natl. Cancer Inst.*, vol. 96, no. 4, pp. 261–268, Feb. 2004, doi: 10.1093/jnci/djh034.
- [38].W. M. Grady and J. M. Carethers, "Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis," *Gastroenterology*, vol. 135, no. 4. W.B. Saunders, pp. 1079–1099, Oct. 01, 2008, doi: 10.1053/j.gastro.2008.07.076.
- [39].M. S. Pino and D. C. Chung, "The Chromosomal Instability Pathway in Colon Cancer," *Gastroenterology*, vol. 138, no. 6, pp. 2059–2072, May 2010, doi: 10.1053/j.gastro.2009.12.065.
- [40].C. R. Boland and A. Goel, "Microsatellite Instability in Colorectal Cancer," *Gastroenterology*, vol. 138, no. 6, pp. 2073–2087.e3, May 2010, doi: 10.1053/j.gastro.2009.12.064.
- [41].A. Umar et al., "Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability," *J. Natl. Cancer Inst.*, vol. 96, no. 4, pp. 261–268, Feb. 2004, doi: 10.1093/jnci/djh034.
- [42].V. V. Lao and W. M. Grady, "Epigenetics and colorectal cancer," *Nature Reviews Gastroenterology and Hepatology*, vol. 8, no. 12. Nature Publishing Group, pp. 686–700, Nov. 18, 2011, doi: 10.1038/nrgastro.2011.173.
- [43].D. J. Weisenberger et al., "CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer," *Nat. Genet.*, vol. 38, no. 7, pp. 787–793, Jul. 2006, doi: 10.1038/ng1834.
- [44].A. T. Chan and E. L. Giovannucci, "Primary Prevention of Colorectal Cancer," *Gastroenterology*, vol. 138, no. 6, 2010, doi: 10.1053/j.gastro.2010.01.057.
- [45].E. A. Platz, W. C. Willett, G. A. Colditz, E. B. Rimm, D. Spiegelman, and E. Giovannucci, "Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men," *Cancer Causes Control*, vol. 11, no. 7, pp. 579–588, 2000, doi: 10.1023/A:1008999232442.
- [46].M. H. Forouzanfar et al., "Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015," *Lancet*, vol. 388, no. 10053, pp. 1659–1724, Oct. 2016, doi: 10.1016/S0140-6736(16)31679-8.
- [47].J. A. Wilschut, E. W. Steyerberg, M. E. Van Leerdam, I. Lansdorp-Vogelaar, J. D. F. Habbema, and M. Van Ballegooijen, "How much colonoscopy screening should be recommended to individuals with

- various degrees of family history of colorectal cancer?," *Cancer*, vol. 117, no. 18, pp. 4166–4174, Sep. 2011, doi: 10.1002/cncr.26009.
- [48].K. W. Jasperson, T. M. Tuohy, D. W. Neklason, and R. W. Burt, "Hereditary and Familial Colon Cancer," *Gastroenterology*, vol. 138, no. 6, pp. 2044–2058, 2010, doi: 10.1053/j.gastro.2010.01.054.
- [49].M. Gala and D. C. Chung, "Hereditary colon cancer syndromes," *Semin. Oncol.*, vol. 38, no. 4, pp. 490–499, 2011, doi: 10.1053/j.seminoncol.2011.05.003.
- [50].K. Zhang, J. Civan, S. Mukherjee, F. Patel, and H. Yang, "Genetic variations in colorectal cancer risk and clinical outcome," *World J. Gastroenterol.*, vol. 20, no. 15, pp. 4167–4177, Apr. 2014, doi: 10.3748/wjg.v20.i15.4167.
- [51].R. W. Burt, J. A. DiSario, and L. Cannon-Albright, "Genetics of colon cancer: Impact of inheritance on colon cancer risk," *Annual Review of Medicine*, vol. 46. *Annu Rev Med*, pp. 371–379, 1995, doi: 10.1146/annurev.med.46.1.371.
- [52].S. A. Bingham et al., "Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study," *Lancet*, vol. 361, no. 9368, pp. 1496–1501, May 2003, doi: 10.1016/S0140-6736(03)13174-1.
- [53].Y. Park et al., "Dietary fiber intake and risk of colorectal cancer: A pooled analysis of prospective cohort studies," *J. Am. Med. Assoc.*, vol. 294, no. 22, pp. 2849–2857, Dec. 2005, doi: 10.1001/jama.294.22.2849.
- [54].A. Koushik et al., "Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies," *J. Natl. Cancer Inst.*, vol. 99, no. 19, pp. 1471–1483, Oct. 2007, doi: 10.1093/jnci/djm155.
- [55].N. J. Ollberding, L. R. Wilkens, B. E. Henderson, L. N. Kolonel, and L. Le Marchand, "Meat consumption, heterocyclic amines and colorectal cancer risk: The Multiethnic Cohort Study," *Int. J. Cancer*, vol. 131, no. 7, Oct. 2012, doi: 10.1002/ijc.27546.
- [56].D. J. Robertson et al., "Fat, fiber, meat and the risk of colorectal adenomas," *Am. J. Gastroenterol.*, vol. 100, no. 12, pp. 2789–2795, Dec. 2005, doi: 10.1111/j.1572-0241.2005.00336.x.
- [57].T. Norat et al., "Meat, fish, and colorectal cancer risk: The European prospective investigation into cancer and nutrition," *J. Natl. Cancer Inst.*, vol. 97, no. 12, pp. 906–916, Jun. 2005, doi: 10.1093/jnci/dji164.
- [58].A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, "Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies," *Lancet*, vol. 371, no. 9612, pp. 569–578, 2008, doi: 10.1016/S0140-6736(08)60269-X.
- [59].T. Boyle, T. Keegel, F. Bull, J. Heyworth, and L. Fritschi, "Physical activity and risks of proximal and distal colon cancers: A systematic review and meta-analysis," *Journal of the National Cancer Institute*, vol. 104, no. 20. *J Natl Cancer Inst*, pp. 1548–1561, Oct. 17, 2012, doi: 10.1093/jnci/djs354.
- [60].K. Y. Wolin, Y. Yan, G. A. Colditz, and I. M. Lee, "Physical activity and colon cancer prevention: A meta-analysis," *Br. J. Cancer*, vol. 100, no. 4, pp. 611–616, Feb. 2009, doi: 10.1038/sj.bjc.6604917.
- [61].T. Mizoue et al., "Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies.," *Am. J. Epidemiol.*, vol. 167, no. 12, pp. 1397–1406, 2008, doi: 10.1093/aje/kwn073.

- [62].J. A. Abrams, M. B. Terry, and A. I. Neugut, "Cigarette Smoking and the Colorectal Adenoma-Carcinoma Sequence," *Gastroenterology*, vol. 134, no. 2. W.B. Saunders, pp. 617–619, 2008, doi: 10.1053/j.gastro.2007.12.015.
- [63].P. M. Rothwell et al., "Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials," *Lancet*, vol. 376, no. 9754, pp. 1741–1750, 2010, doi: 10.1016/S0140-6736(10)61543-7.
- [64].J. A. Baron et al., "A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas," *Gastroenterology*, vol. 131, no. 6, pp. 1674–1682, 2006, doi: 10.1053/j.gastro.2006.08.079.
- [65].J. Burn et al., "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial," *Lancet*, vol. 378, no. 9809, pp. 2081–2087, 2011, doi: 10.1016/S0140-6736(11)61049-0.
- [66].G. P. Young and S. Cole, "New stool screening tests for colorectal cancer," *Digestion*, vol. 76, no. 1. *Digestion*, pp. 26–33, Oct. 2007, doi: 10.1159/000108391.
- [67].D. H. Greegor, "Detection of Silent Colon Cancer in Routine Examination," *CA. Cancer J. Clin.*, vol. 19, no. 6, pp. 330–337, Nov. 1969, doi: 10.3322/canjclin.19.6.330.
- [68].D. H. Greegor, "Diagnosis of Large-Bowel Cancer in the Asymptomatic Patient," *JAMA J. Am. Med. Assoc.*, vol. 201, no. 12, pp. 943–945, 1967, doi: 10.1001/jama.1967.03130120051012.
- [69].M. Pignone, M. K. Campbell, C. Carr, and C. Phillips, "Meta-analysis of dietary restriction during fecal occult blood testing.," *Eff. Clin. Pract.*, vol. 4, no. 4, pp. 150–156, 2001, Accessed: Mar. 24, 2021. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/11525101/>.
- [70].R. M. Jaffe, B. Kasten, D. S. Young, and J. D. MacLowry, "False negative stool occult blood test caused by ingestion of ascorbic acid (vitamin C)," *Ann. Intern. Med.*, vol. 83, no. 6, pp. 824–826, 1975, doi: 10.7326/0003-4819-83-6-824.
- [71].L. Rabeneck et al., "Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening," *Can. J. Gastroenterol.*, vol. 26, no. 3, pp. 131–147, 2012, doi: 10.1155/2012/486328.
- [72].J. E. Allison et al., "Screening for colorectal neoplasms with new fecal occult blood tests: Update on performance characteristics," *J. Natl. Cancer Inst.*, vol. 99, no. 19, pp. 1462–1470, Oct. 2007, doi: 10.1093/jnci/djm150.
- [73].J. H. Scholefield, S. M. Moss, C. M. Mangham, D. K. Whyntes, and J. D. Hardcastle, "Nottingham trial of faecal occult blood testing for colorectal cancer: A 20-year follow-up," *Gut*, vol. 61, no. 7, pp. 1036–1040, Jul. 2012, doi: 10.1136/gutjnl-2011-300774.
- [74].G. Spinzi and G. Minoli, "A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy.," *Gastrointest. Endosc.*, vol. 54, no. 3, pp. 417–418, Sep. 2001, doi: 10.1056/nejm200006153422401.
- [75].C. L. Canon, "Is There Still a Role for Double-Contrast Barium Enema Examination?," *Clin. Gastroenterol. Hepatol.*, vol. 6, no. 4, pp. 389–392, Apr. 2008, doi: 10.1016/j.cgh.2007.12.051.
- [76].D. J. Vining, "Virtual endoscopy: is it reality?," *Radiology*, vol. 200, no. 1, pp. 30–31, Jul. 01, 1996, doi: 10.1148/radiology.200.1.8657938.

- [77].C. L. Kay and H. A. Evangelou, "A review of the technical and clinical aspects of virtual endoscopy," *Endoscopy*, vol. 28, no. 9. Georg Thieme Verlag, pp. 768–775, Nov. 17, 1996, doi: 10.1055/s-2007-1005603.
- [78].M. C. De Haan, R. E. Van Gelder, A. Graser, S. Bipat, and J. Stoker, "Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: A meta-analysis," *Eur. Radiol.*, vol. 21, no. 8, pp. 1747–1763, Aug. 2011, doi: 10.1007/s00330-011-2104-8.
- [79].J. E. Martín-López, C. Beltrán-Calvo, R. Rodríguez-López, and T. Molina-López, "Comparison of the accuracy of CT colonography and colonoscopy in the diagnosis of colorectal cancer," *Colorectal Disease*, vol. 16, no. 3. *Colorectal Dis*, Mar. 2014, doi: 10.1111/codi.12506.
- [80].M. E. Zalis et al., "Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults, A prospective evaluation," *Ann. Intern. Med.*, vol. 156, no. 10, pp. 692–702, 2012, doi: 10.7326/0003-4819-156-10-201205150-00005.
- [81].N. Schoofs, J. Devière, and A. Van Gossum, "PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: A prospective pilot study," *Endoscopy*, vol. 38, no. 10, pp. 971–977, Oct. 2006, doi: 10.1055/s-2006-944835.
- [82].T. Rokkas, K. Papaxoinis, K. Triantafyllou, and S. D. Ladas, "A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps," *Gastrointest. Endosc.*, vol. 71, no. 4, pp. 792–798, Apr. 2010, doi: 10.1016/j.gie.2009.10.050.
- [83].R. Eliakim et al., "Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy," *Endoscopy*, vol. 41, no. 12, pp. 1026–1031, 2009, doi: 10.1055/s-0029-1215360.
- [84].C. Spada et al., "Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline," *Endoscopy*, vol. 44, no. 5. *Endoscopy*, pp. 527–536, 2012, doi: 10.1055/s-0031-1291717.
- [85].W. G. Kwack and Y. J. Lim, "Current status and research into overcoming limitations of capsule endoscopy," *Clinical Endoscopy*, vol. 49, no. 1. Korean Society of Gastrointestinal Endoscopy, pp. 8–15, Jan. 01, 2016, doi: 10.5946/ce.2016.49.1.8.
- [86].R. H. Fletcher, "Rationale for combining different screening strategies," *Gastrointestinal Endoscopy Clinics of North America*, vol. 12, no. 1. W.B. Saunders, pp. 53–63, Jan. 2002, doi: 10.1016/S1052-5157(03)00057-6.
- [87].H. Brenner, C. Stock, and M. Hoffmeister, "Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: Systematic review and meta-analysis of randomised controlled trials and observational studies," *BMJ*, vol. 348, Apr. 2014, doi: 10.1136/bmj.g2467.
- [88].B. J. Elmunzer, R. A. Hayward, P. S. Schoenfeld, S. D. Saini, A. Deshpande, and A. K. Waljee, "Effect of Flexible Sigmoidoscopy-Based Screening on Incidence and Mortality of Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials," *PLoS Med.*, vol. 9, no. 12, Dec. 2012, doi: 10.1371/journal.pmed.1001352.
- [89].S. H. Lee, Y. K. Park, D. J. Lee, and K. M. Kim, "Colonoscopy procedural skills and training for new beginners," *World Journal of Gastroenterology*, vol. 20, no. 45. WJG Press, pp. 16984–16995, Dec. 07, 2014, doi: 10.3748/wjg.v20.i45.16984.

- [90].I. Aubin-Auger, A. Mercier, J. P. Lebeau, L. Baumann, L. Peremans, and P. Van royen, "Obstacles to colorectal screening in general practice: A qualitative study of GPs and patients," *Fam. Pract.*, vol. 28, no. 6, pp. 670–676, Dec. 2011, doi: 10.1093/fampra/cm110.
- [91].C. Lionis and E. Petelos, "Early detection of colorectal cancer: Barriers to screening in the primary care setting," *Family Practice*, vol. 28, no. 6. *Fam Pract*, pp. 589–591, Dec. 2011, doi: 10.1093/fampra/cm110.
- [92].D. J. Holden, D. E. Jonas, D. S. Porterfield, D. Reuland, and R. Harris, "Systematic review: Enhancing the use and quality of colorectal cancer screening," in *Annals of Internal Medicine*, May 2010, vol. 152, no. 10, pp. 668–676, doi: 10.7326/0003-4819-152-10-201005180-00239.
- [93].M. L. Brown and A. L. Potosky, "The presidential effect: The public health response to media coverage about ronald reagan's colon cancer episode," *Public Opin. Q.*, vol. 54, no. 3, pp. 317–329, Sep. 1990, doi: 10.1086/269209.
- [94].S. M. Noar, J. F. Willoughby, J. G. Myrick, and J. Brown, "Public Figure Announcements About Cancer and Opportunities for Cancer Communication: A Review and Research Agenda," *Health Commun.*, vol. 29, no. 5, pp. 445–461, May 2014, doi: 10.1080/10410236.2013.764781.
- [95].C. Twine, L. Barthelmes, and C. A. Gateley, "Kylie Minogue's breast cancer: Effects on referrals to a rapid access breast clinic in the UK," *Breast*, vol. 15, no. 5, pp. 667–669, Oct. 2006, doi: 10.1016/j.breast.2006.03.006.
- [96].B. Kelly et al., "Cancer information scanning and seeking in the general population," *J. Health Commun.*, vol. 15, no. 7, pp. 734–753, Oct. 2010, doi: 10.1080/10810730.2010.514029.
- [97].J. M. E. Walsh, S. F. Posner, and E. J. Perez-Stable, "Colon cancer screening in the ambulatory setting," *Prev. Med. (Baltim.)*, vol. 35, no. 3, pp. 209–218, 2002, doi: 10.1006/pmed.2002.1059.
- [98].M. Jakovljevic et al., "Do health reforms impact cost consciousness of health care professionals? Results from a Nation-wide survey in the Balkans," *Balkan Med. J.*, vol. 33, no. 1, pp. 8–17, Feb. 2016, doi: 10.5152/balkanmedj.2015.15869.
- [99].C. G. Willett, D. T. Chang, B. G. Czito, J. Meyer, and J. Wo, "Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012. (5)," *International Journal of Radiation Oncology Biology Physics*, vol. 86, no. 1. Elsevier Inc., p. 2, May 01, 2013, doi: 10.1016/j.ijrobp.2012.12.006.
- [100].M. Brocardo and B. R. Henderson, "APC shuttling to the membrane, nucleus and beyond," *Trends in Cell Biology*, vol. 18, no. 12. Elsevier, pp. 587–596, Dec. 01, 2008, doi: 10.1016/j.tcb.2008.09.002.
- [101].D. O. Herzig and V. L. Tsikitis, "Molecular markers for colon diagnosis, prognosis and targeted therapy," *J. Surg. Oncol.*, vol. 111, no. 1, pp. 96–102, Jan. 2015, doi: 10.1002/jso.23806.
- [102].S. Rennoll and G. Yochum, "Regulation of MYC gene expression by aberrant Wnt/ $\beta$ -catenin signaling in colorectal cancer.," *World J. Biol. Chem.*, vol. 6, no. 4, pp. 290–300, Nov. 2015, doi: 10.4331/wjbc.v6.i4.290.
- [103].C. W. Toon et al., "Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer," *PLoS One*, vol. 9, no. 2, p. e87456, Feb. 2014, doi: 10.1371/journal.pone.0087456.

- [104].J. Chen et al., “BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients,” *BMC Cancer*, vol. 14, no. 1, p. 802, Nov. 2014, doi: 10.1186/1471-2407-14-802.
- [105].W. Li et al., “Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages,” *BMC Cancer*, vol. 15, no. 1, p. 340, May 2015, doi: 10.1186/s12885-015-1345-3.
- [106].S. Ogino et al., “CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer,” *Gut*, vol. 58, no. 1, pp. 90–96, Jan. 2009, doi: 10.1136/gut.2008.155473.
- [107].J. Goldstein et al., “Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H),” *Ann. Oncol.*, vol. 25, no. 5, pp. 1032–1038, May 2014, doi: 10.1093/annonc/mdu100.
- [108].S. Kadowaki et al., “Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer,” *World J. Gastroenterol.*, vol. 21, no. 4, pp. 1275–1283, Jan. 2015, doi: 10.3748/wjg.v21.i4.1275.
- [109].R. Yaeger et al., “Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients,” *Clin. Cancer Res.*, vol. 21, no. 6, pp. 1313–1320, Mar. 2015, doi: 10.1158/1078-0432.CCR-14-2779.
- [110].M. Morkel, P. Riemer, H. Bläker, and C. Sers, “Similar but different: Distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance,” *Oncotarget*, vol. 6, no. 25, pp. 20785–20800, Jul. 2015, doi: 10.18632/oncotarget.4750.
- [111].C. Rosty et al., “PIK3CA Activating Mutation in Colorectal Carcinoma: Associations with Molecular Features and Survival,” *PLoS One*, vol. 8, no. 6, p. e65479, Jun. 2013, doi: 10.1371/journal.pone.0065479.
- [112].X. Liao et al., “Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review,” *Clin. Cancer Res.*, vol. 18, no. 8, pp. 2257–2268, Apr. 2012, doi: 10.1158/1078-0432.CCR-11-2410.
- [113].C. E. Atreya et al., “PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival,” *Cancer Med.*, vol. 2, no. 4, pp. 496–506, Aug. 2013, doi: 10.1002/cam4.97.
- [114].J. S. Mattick and I. V. Makunin, “Non-coding RNA,” *Human molecular genetics*, vol. 15 Spec No, no. suppl\_1. Oxford Academic, pp. R17–R29, Apr. 15, 2006, doi: 10.1093/hmg/ddl046.
- [115].K. V. Morris and J. S. Mattick, “The rise of regulatory RNA,” *Nature Reviews Genetics*, vol. 15, no. 6. Nature Publishing Group, pp. 423–437, Apr. 29, 2014, doi: 10.1038/nrg3722.
- [116].L. Nie et al., “Long non-coding RNAs: Versatile master regulators of gene expression and crucial players in cancer,” *American Journal of Translational Research*, vol. 4, no. 2. pp. 127–150, 2012, Accessed: Apr. 01, 2021. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/22611467/>.
- [117].M. J. Hamilton, M. D. Young, S. Sauer, and E. Martinez, “The interplay of long non-coding RNAs and MYC in cancer,” *AIMS Biophysics*, vol. 2, no. 4. American Institute of Mathematical Sciences, pp. 794–809, 2015, doi: 10.3934/biophy.2015.4.794.

- [118].E. A. Gibb, C. J. Brown, and W. L. Lam, “The functional role of long non-coding RNA in human carcinomas,” *Molecular Cancer*, vol. 10, no. 1. BioMed Central, pp. 1–17, Apr. 13, 2011, doi: 10.1186/1476-4598-10-38.
- [119].Y. Fellig et al., “H19 expression in hepatic metastases from a range of human carcinomas,” *J. Clin. Pathol.*, vol. 58, no. 10, pp. 1064–1068, Oct. 2005, doi: 10.1136/jcp.2004.023648.
- [120].W. P. Tsang et al., “Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer,” *Carcinogenesis*, vol. 31, no. 3, pp. 350–358, Mar. 2010, doi: 10.1093/carcin/bgp181.
- [121].P. Ohana et al., “Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases,” *J. Gene Med.*, vol. 7, no. 3, pp. 366–374, Mar. 2005, doi: 10.1002/jgm.670.
- [122].P. Schorderet and D. Duboule, “Structural and functional differences in the long non-coding RNA hotair in mouse and human,” *PLoS Genet.*, vol. 7, no. 5, p. e1002071, May 2011, doi: 10.1371/journal.pgen.1002071.
- [123].R. A. Gupta et al., “Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis,” *Nature*, vol. 464, no. 7291, pp. 1071–1076, Apr. 2010, doi: 10.1038/nature08975.
- [124].C. Xu, M. Yang, J. Tian, X. Wang, and Z. Li, “MALAT-1: A long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis,” *Int. J. Oncol.*, vol. 39, no. 1, pp. 169–175, Jul. 2011, doi: 10.3892/ijo.2011.1007.
- [125].X. Zhang et al., “A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells,” *J. Clin. Endocrinol. Metab.*, vol. 88, no. 11, pp. 5119–5126, Nov. 2003, doi: 10.1210/jc.2003-030222.
- [126].F. Yang et al., “Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma,” *J. Cancer Res. Clin. Oncol.*, vol. 139, no. 3, pp. 437–445, Mar. 2013, doi: 10.1007/s00432-012-1324-x.
- [127].T. Kim et al., “Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 111, no. 11, pp. 4173–4178, Mar. 2014, doi: 10.1073/pnas.1400350111.
- [128].H. Ling et al., “CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer,” *Genome Res.*, vol. 23, no. 9, pp. 1446–1461, Sep. 2013, doi: 10.1101/gr.152942.112.
- [129].L. D. Graham et al., “Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas,” *Genes Cancer*, vol. 2, no. 8, pp. 829–40, Aug. 2011, doi: 10.1177/1947601911431081.
- [130].L. Pibouin et al., “Cloning of the mRNA of overexpression in colon carcinoma-1: A sequence overexpressed in a subset of colon carcinomas,” *Cancer Genet. Cytogenet.*, vol. 133, no. 1, pp. 55–60, Feb. 2002, doi: 10.1016/S0165-4608(01)00634-3.
- [131].L. Poliseno, L. Salmena, J. Zhang, B. Carver, W. J. Haveman, and P. P. Pandolfi, “A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,” *Nature*, vol. 465, no. 7301, pp. 1033–1038, Jun. 2010, doi: 10.1038/nature09144.



- [132].Y. J. Han, S. F. Ma, G. Yourek, Y. Park, and J. G. N. Garcia, "A transcribed pseudogene of MYLK promotes cell proliferation," *FASEB J.*, vol. 25, no. 7, pp. 2305–2312, Jul. 2011, doi: 10.1096/fj.10-177808.
- [133].I. Panagopoulos, E. Möller, A. Collin, and F. Mertens, "The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1," *Oncol. Rep.*, vol. 20, no. 5, pp. 1029–1033, Nov. 2008, doi: 10.3892/or\_00000105.
- [134].F. Wang, X. Li, X. Xie, L. Zhao, and W. Chen, "UCA1 , a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion," *FEBS Lett.*, vol. 582, no. 13, pp. 1919–1927, Jun. 2008, doi: 10.1016/j.febslet.2008.05.012.
- [135].S. Chung et al., "Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility," *Cancer Sci.*, vol. 102, no. 1, pp. 245–252, Jan. 2011, doi: 10.1111/j.1349-7006.2010.01737.x.
- [136].L. Li et al., "Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer," *J. Exp. Clin. Cancer Res.*, vol. 32, no. 1, p. 104, Dec. 2013, doi: 10.1186/1756-9966-32-104.
- [137].F. Yang et al., "Repression of the Long Noncoding RNA-LET by Histone Deacetylase 3 Contributes to Hypoxia-Mediated Metastasis," *Mol. Cell*, vol. 49, no. 6, pp. 1083–1096, Mar. 2013, doi: 10.1016/j.molcel.2013.01.010.
- [138].P. Qi et al., "Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients," *Mol. Carcinog.*, vol. 54, no. 9, pp. 742–750, Sep. 2015, doi: 10.1002/mc.22137.
- [139].Y. Takahashi et al., "Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers," *Br. J. Cancer*, vol. 110, no. 1, pp. 164–171, Nov. 2014, doi: 10.1038/bjc.2013.698.
- [140].Y. Y. Tseng et al., "PVT1 dependence in cancer with MYC copy-number increase," *Nature*, vol. 512, no. 1, pp. 82–86, Jun. 2014, doi: 10.1038/nature13311.
- [141].F. E. Ahmed et al., "Diagnostic MicroRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle," *Cancer Genomics and Proteomics*, vol. 10, no. 3, pp. 93–113, 2013.
- [142].X. Yang et al., "The expression and clinical significance of microRNAs in colorectal cancer detecting," *Tumor Biol.*, vol. 36, no. 4, pp. 2675–2684, Apr. 2015, doi: 10.1007/s13277-014-2890-0.
- [143].L. K. Ursell, J. L. Metcalf, L. W. Parfrey, and R. Knight, "Defining the human microbiome," *Nutr. Rev.*, vol. 70, no. SUPPL. 1, pp. S38–S44, Aug. 2012, doi: 10.1111/j.1753-4887.2012.00493.x.
- [144].E. Scarpellini, G. Ianiro, F. Attili, C. Bassanelli, A. De Santis, and A. Gasbarrini, "The human gut microbiota and virome: Potential therapeutic implications," *Dig. Liver Dis.*, vol. 47, no. 12, pp. 1007–1012, Dec. 2015, doi: 10.1016/j.dld.2015.07.008.
- [145].J. C. Stearns et al., "Bacterial biogeography of the human digestive tract," *Sci. Rep.*, vol. 1, no. 1, pp. 1–9, Nov. 2011, doi: 10.1038/srep00170.
- [146].M. Rajilić-Stojanović, H. Smidt, and W. M. De Vos, "Diversity of the human gastrointestinal tract microbiota revisited," *Environmental Microbiology*, vol. 9, no. 9. John Wiley & Sons, Ltd, pp. 2125–2136, Sep. 01, 2007, doi: 10.1111/j.1462-2920.2007.01369.x.

- [147].S. Matamoros, C. Gras-Leguen, F. Le Vacon, G. Potel, and M. F. De La Cochetiere, "Development of intestinal microbiota in infants and its impact on health," *Trends in Microbiology*, vol. 21, no. 4. Elsevier, pp. 167–173, Apr. 01, 2013, doi: 10.1016/j.tim.2012.12.001.
- [148].R. E. Ley et al., "Evolution of mammals and their gut microbes," *Science (80-. )*, vol. 320, no. 5883, pp. 1647–1651, Jun. 2008, doi: 10.1126/science.1155725.
- [149].E. R. Davenport, O. Mizrahi-Man, K. Michelini, L. B. Barreiro, C. Ober, and Y. Gilad, "Seasonal variation in human gut microbiome composition," *PLoS One*, vol. 9, no. 3, p. e90731, Mar. 2014, doi: 10.1371/journal.pone.0090731.
- [150].S. A. Sankar, J. C. Lagier, P. Pontarotti, D. Raoult, and P. E. Fournier, "The human gut microbiome, a taxonomic conundrum," *Systematic and Applied Microbiology*, vol. 38, no. 4. Elsevier GmbH, pp. 276–286, Jun. 01, 2015, doi: 10.1016/j.syapm.2015.03.004.
- [151].M. J. Cox, W. O. C. M. Cookson, and M. F. Moffatt, "Sequencing the human microbiome in health and disease," *Hum. Mol. Genet.*, vol. 22, no. R1, pp. R88–R94, Oct. 2013, doi: 10.1093/hmg/ddt398.
- [152].D. R. Garza and B. E. Dutilh, "From cultured to uncultured genome sequences: Metagenomics and modeling microbial ecosystems," *Cellular and Molecular Life Sciences*, vol. 72, no. 22. Birkhauser Verlag AG, pp. 4287–4308, Nov. 01, 2015, doi: 10.1007/s00018-015-2004-1.
- [153].M. B. Geuking, Y. Köller, S. Rupp, and K. D. McCoy, "The interplay between the gut microbiota and the immune system," *Gut Microbes*, vol. 5, no. 3. Landes Bioscience, pp. 411–418, May 12, 2014, doi: 10.4161/gmic.29330.
- [154].H. Chung and D. L. Kasper, "Microbiota-stimulated immune mechanisms to maintain gut homeostasis," *Current Opinion in Immunology*, vol. 22, no. 4. Elsevier Current Trends, pp. 455–460, Aug. 01, 2010, doi: 10.1016/j.coi.2010.06.008.
- [155].S. Krishnan, N. Alden, and K. Lee, "Pathways and functions of gut microbiota metabolism impacting host physiology," *Current Opinion in Biotechnology*, vol. 36. Elsevier Ltd, pp. 137–145, Dec. 01, 2015, doi: 10.1016/j.copbio.2015.08.015.
- [156].Y. G. Kim, K. G. S. Udayanga, N. Totsuka, J. B. Weinberg, G. Núñez, and A. Shibuya, "Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE<sub>2</sub>," *Cell Host Microbe*, vol. 15, no. 1, pp. 95–102, Jan. 2014, doi: 10.1016/j.chom.2013.12.010.
- [157].J. Zimmer et al., "A vegan or vegetarian diet substantially alters the human colonic faecal microbiota," *Eur. J. Clin. Nutr.*, vol. 66, no. 1, pp. 53–60, Jan. 2012, doi: 10.1038/ejcn.2011.141.
- [158].L. A. David et al., "Diet rapidly and reproducibly alters the human gut microbiome," *Nature*, vol. 505, no. 7484, pp. 559–563, Dec. 2014, doi: 10.1038/nature12820.
- [159].R. J. Hung et al., "Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer," *J. Natl. Cancer Inst.*, vol. 107, no. 11, p. djv246, Nov. 2015, doi: 10.1093/jnci/djv246.
- [160].E. Z. P. Chai, K. S. Siveen, M. K. Shanmugam, F. Arfuso, and G. Sethi, "Analysis of the intricate relationship between chronic inflammation and cancer," *Biochemical Journal*, vol. 468, no. 1. Portland Press Ltd, pp. 1–15, May 15, 2015, doi: 10.1042/BJ20141337.

- [161].G. Tomasello et al., “Dismicrobism in inflammatory bowel disease and colorectal cancer: Changes in response of colocytes,” *World J. Gastroenterol.*, vol. 20, no. 48, pp. 18121–18130, Dec. 2014, doi: 10.3748/wjg.v20.i48.18121.
- [162].B. M. Ryan et al., “An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer,” *Cancer Epidemiol.*, vol. 38, no. 5, pp. 583–590, Oct. 2014, doi: 10.1016/j.canep.2014.07.003.
- [163].H. Nagao-Kitamoto, S. Kitamoto, P. Kuffa, and N. Kamada, “Pathogenic role of the gut microbiota in gastrointestinal diseases,” *Intestinal Research*, vol. 14, no. 2. Korean Association for the Study of Intestinal Diseases, pp. 127–138, 2016, doi: 10.5217/ir.2016.14.2.127.
- [164].J. M. Peloquin and D. D. Nguyen, “The microbiota and inflammatory bowel disease: Insights from animal models,” *Anaerobe*, vol. 24, pp. 102–106, Dec. 2013, doi: 10.1016/j.anaerobe.2013.04.006.
- [165].N. Wu et al., “Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients,” *Microb. Ecol.*, vol. 66, no. 2, pp. 462–470, Aug. 2013, doi: 10.1007/s00248-013-0245-9.
- [166].T. Wang et al., “Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers,” *ISME J.*, vol. 6, no. 2, pp. 320–329, Feb. 2012, doi: 10.1038/ismej.2011.109.
- [167].I. Sobhani et al., “Microbial dysbiosis and colon carcinogenesis: Could colon cancer be considered a bacteria-related disease?,” *Therapeutic Advances in Gastroenterology*, vol. 6, no. 3. SAGE PublicationsSage UK: London, England, pp. 215–229, May 11, 2013, doi: 10.1177/1756283X12473674.
- [168].R. F. Schwabe and C. Jobin, “The microbiome and cancer,” *Nature Reviews Cancer*, vol. 13, no. 11. Nature Publishing Group, pp. 800–812, Oct. 17, 2013, doi: 10.1038/nrc3610.
- [169].Juan Jose Sebastian Domingo and Clara Sanchez, “REED - Revista Española de Enfermedades Digestivas,” *ENFERMEDADES Dig.*, vol. 110, no. 1, pp. 51–56, 2018, Accessed: Apr. 02, 2021. [Online]. Available: <https://www.reed.es/ArticuloFicha.aspx?id=642&hst=0&idR=30&tp=1&AspxAutoDetectCookieSupport=1>.
- [170].M. Candela et al., “Inflammation and colorectal cancer, when microbiota-host mutualism breaks,” *World J. Gastroenterol.*, vol. 20, no. 4, pp. 908–922, 2014, doi: 10.3748/wjg.v20.i4.908.
- [171].J. P. Zackular et al., “The gut microbiome modulates colon tumorigenesis,” *MBio*, vol. 4, no. 6, pp. 692–705, Nov. 2013, doi: 10.1128/mBio.00692-13.
- [172].P. A. Farazi, “Cancer trends and risk factors in Cyprus,” *Ecancermedicalscience*, vol. 8, no. 1, Jan. 2014, doi: 10.3332/ecancer.2014.389.
- [173].S. Koifman and R. J. Koifman, “Environment and cancer in Brazil: An overview from a public health perspective,” in *Mutation Research - Reviews in Mutation Research*, Nov. 2003, vol. 544, no. 2–3, pp. 305–311, doi: 10.1016/j.mrrev.2003.07.005.
- [174].N. F. Aykan, “Red meat and colorectal cancer,” *Oncology Reviews*, vol. 9, no. 1. Page Press Publications, pp. 38–44, Dec. 28, 2015, doi: 10.4081/oncol.2015.288.
- [175].E. Kim, D. Coelho, and F. Blachier, “Review of the association between meat consumption and risk of colorectal cancer,” *Nutrition Research*, vol. 33, no. 12. Elsevier, pp. 983–994, Dec. 01, 2013, doi: 10.1016/j.nutres.2013.07.018.

- [176].J. Ou et al., "Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans," *Am. J. Clin. Nutr.*, vol. 98, no. 1, pp. 111–120, Jul. 2013, doi: 10.3945/ajcn.112.056689.
- [177].Q. Feng et al., "Gut microbiome development along the colorectal adenoma-carcinoma sequence," *Nat. Commun.*, vol. 6, no. 1, pp. 1–13, Mar. 2015, doi: 10.1038/ncomms7528.
- [178].S. J. D. O’Keefe et al., "Fat, fibre and cancer risk in African Americans and rural Africans," *Nat. Commun.*, vol. 6, no. 1, pp. 1–14, Apr. 2015, doi: 10.1038/ncomms7342.
- [179].D. R. Donohoe et al., "A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner," *Cancer Discov.*, vol. 4, no. 12, pp. 1387–1397, Dec. 2014, doi: 10.1158/2159-8290.CD-14-0501.
- [180].E. P. Diamandis, "Cancer biomarkers: Can we turn recent failures into success?," *Journal of the National Cancer Institute*, vol. 102, no. 19. Oxford University Press, pp. 1462–1467, Oct. 06, 2010, doi: 10.1093/jnci/djq306.
- [181].J. A. Ludwig and J. N. Weinstein, "Biomarkers in cancer staging, prognosis and treatment selection," *Nature Reviews Cancer*, vol. 5, no. 11. Nature Publishing Group, pp. 845–856, Nov. 20, 2005, doi: 10.1038/nrc1739.
- [182].C. Coghlin and G. I. Murray, "Biomarkers of colorectal cancer: Recent advances and future challenges," *Proteomics - Clinical Applications*, vol. 9, no. 1–2. Wiley-VCH Verlag, pp. 64–71, Feb. 01, 2015, doi: 10.1002/prca.201400082.
- [183].F. Bertucci et al., "Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters," *Oncogene*, vol. 23, no. 7, pp. 1377–1391, Feb. 2004, doi: 10.1038/sj.onc.1207262.
- [184].M. A. Imran and H. Shahid, "A Review-Anti-Cancer Compounds from Medicinal Plants: Isolation, Identification, and Characterization," *Int. J. Biosci.*, vol. 17, no. December, pp. 442–468, 2020, doi: 10.12692/ijb/17.6.442-468.
- [185].E. Van Cutsem, A. Cervantes, B. Nordlinger, D. Arnold, and The ESMO Guidelines Working Group, "Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up," *Ann. Oncol.*, vol. 25, pp. iii1–iii9, Sep. 2014, doi: 10.1093/annonc/mdu260.
- [186].E. van Cutsem, B. Nordlinger, and A. Cervantes, "Advanced colorectal cancer: ESMO clinical practice guidelines for treatment," *Ann. Oncol.*, vol. 21, no. SUPPL. 5, pp. 93–97, May 2010, doi: 10.1093/annonc/mdq222.
- [187].J. W. Bacher et al., "Development of a fluorescent multiplex assay for detection of MSI-high tumors," in *Disease Markers*, 2004, vol. 20, no. 4–5, pp. 237–250, doi: 10.1155/2004/136734.
- [188].K. B. Geiersbach and W. S. Samowitz, "Microsatellite instability and colorectal cancer," *Archives of Pathology and Laboratory Medicine*, vol. 135, no. 10. Allen Press, pp. 1269–1277, Oct. 01, 2011, doi: 10.5858/arpa.2011-0035-RA.
- [189].B. Iacopetta and T. Watanabe, "Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer [14]," *Gut*, vol. 55, no. 11. pp. 1671–1672, 2006, Accessed: Apr. 17, 2021. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/17047121/>.

- [190].D. Kislitsin, A. Lerner, G. Rennert, and Z. Lev, “K-ras mutations in sporadic colorectal tumors in Israel: Unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes,” *Dig. Dis. Sci.*, vol. 47, no. 5, pp. 1073–1079, 2002, doi: 10.1023/A:1015090124153.
- [191].W. De Roock et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis,” *Lancet Oncol.*, vol. 11, no. 8, pp. 753–762, Aug. 2010, doi: 10.1016/S1470-2045(10)70130-3.
- [192].G. Aprile, M. Macerelli, M. De, S. Pizzolitto, and G. Fasola, “The relevance of BRAF and extended RAS mutational analyses for metastatic colorectal cancer patients,” *OA Mol. Oncol.*, vol. 1, no. 1, 2013, doi: 10.13172/2052-9635-1-1-1148.
- [193].R. Wong and D. Cunningham, “Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies,” *Journal of Clinical Oncology*, vol. 26, no. 35. American Society of Clinical Oncology, pp. 5668–5670, Dec. 10, 2008, doi: 10.1200/JCO.2008.19.5024.
- [194].K. Fransén, M. Klintonäs, A. Österström, J. Dimberg, H. J. Monstein, and P. Söderkvist, “Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas,” *Carcinogenesis*, vol. 25, no. 4, pp. 527–533, Oct. 2004, doi: 10.1093/carcin/bgh049.
- [195].J. M. D. Wheeler, A. Loukola, L. A. Aaltonen, N. J. McC Mortensen, and W. F. Bodmer, “The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI + sporadic colorectal cancers,” *J. Med. Genet.*, vol. 37, no. 8, pp. 588–592, Aug. 2000, doi: 10.1136/jmg.37.8.588.
- [196].N. Umetani et al., “Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats,” *Clin. Chem.*, vol. 52, no. 6, pp. 1062–1069, Jun. 2006, doi: 10.1373/clinchem.2006.068577.
- [197].Y. Wang et al., “Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer,” *J. Clin. Oncol.*, vol. 22, no. 9, pp. 1564–1571, May 2004, doi: 10.1200/JCO.2004.08.186.
- [198].A. Barrier et al., “Stage II colon cancer prognosis prediction by tumor gene expression profiling,” *J. Clin. Oncol.*, vol. 24, no. 29, pp. 4685–4691, Oct. 2006, doi: 10.1200/JCO.2005.05.0229.
- [199].T. Takai et al., “Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening,” *Cancer Epidemiol. Biomarkers Prev.*, vol. 18, no. 6, pp. 1888–1893, Jun. 2009, doi: 10.1158/1055-9965.EPI-08-0937.
- [200].S. Khambata-Ford et al., “Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab,” *J. Clin. Oncol.*, vol. 25, no. 22, pp. 3230–3237, Aug. 2007, doi: 10.1200/JCO.2006.10.5437.
- [201].B. Jacobs et al., “Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab,” *J. Clin. Oncol.*, vol. 27, no. 30, pp. 5068–5074, Oct. 2009, doi: 10.1200/JCO.2008.21.3744.

- [202].S. Hundt, U. Haug, and H. Brenner, "Blood markers for early detection of colorectal cancer: A systematic review," *Cancer Epidemiology Biomarkers and Prevention*, vol. 16, no. 10. American Association for Cancer Research, pp. 1935–1953, Oct. 01, 2007, doi: 10.1158/1055-9965.EPI-06-0994.
- [203].I. K. Quaye, "Haptoglobin, inflammation and disease," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 102, no. 8. Oxford Academic, pp. 735–742, Aug. 01, 2008, doi: 10.1016/j.trstmh.2008.04.010.
- [204].S. J. Cohen et al., "Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer," *Ann. Oncol.*, vol. 20, no. 7, pp. 1223–1229, Jul. 2009, doi: 10.1093/annonc/mdn786.
- [205].J. Sastre et al., "Circulating tumor cells in colorectal cancer: Correlation with clinical and pathological variables," *Ann. Oncol.*, vol. 19, no. 5, pp. 935–938, May 2008, doi: 10.1093/annonc/mdm583.
- [206].Y. H. Uen et al., "Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection," *Ann. Surg. Oncol.*, vol. 15, no. 8, pp. 2120–2128, Aug. 2008, doi: 10.1245/s10434-008-9961-7.
- [207].K. T. Yip, P. K. Das, D. Suria, C. R. Lim, G. H. Ng, and C. C. Liew, "A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia," *J. Exp. Clin. Cancer Res.*, vol. 29, no. 1, p. 128, Sep. 2010, doi: 10.1186/1756-9966-29-128.
- [208].K. W. Marshall et al., "A blood-based biomarker panel for stratifying current risk for colorectal cancer," *Int. J. Cancer*, vol. 126, no. 5, pp. 1177–1186, Mar. 2010, doi: 10.1002/ijc.24910.
- [209].G. Srivastava et al., "Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients," *Oncologist*, vol. 19, no. 5, pp. 492–497, May 2014, doi: 10.1634/theoncologist.2013-0401.
- [210].G. Yothers et al., "Validation of the 12-gene colon cancer Recurrence Score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin," *J. Clin. Oncol.*, vol. 31, no. 36, pp. 4512–4519, Dec. 2013, doi: 10.1200/JCO.2012.47.3116.
- [211].R. Salazar et al., "Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer," *J. Clin. Oncol.*, vol. 29, no. 1, pp. 17–24, Jan. 2011, doi: 10.1200/JCO.2010.30.1077.
- [212].M. Maak et al., "Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer," *Ann. Surg.*, vol. 257, no. 6, pp. 1053–1058, Jun. 2013, doi: 10.1097/SLA.0b013e31827c1180.
- [213].R. D. Kennedy et al., "Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue," *J. Clin. Oncol.*, vol. 29, no. 35, pp. 4620–4626, Dec. 2011, doi: 10.1200/JCO.2011.35.4498.
- [214].A. Sveen et al., "Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: Is godot finally arriving?," *Clinical Cancer Research*, vol. 19, no. 24. American

- Association for Cancer Research, pp. 6669–6677, Dec. 15, 2013, doi: 10.1158/1078-0432.CCR-13-1769.
- [215].P. F. Lenehan et al., “Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma,” *Cancer*, vol. 118, no. 21, pp. 5234–5244, Nov. 2012, doi: 10.1002/cncr.27628.
- [216].M. R. Carlson, “Previstagetrade; GCC colorectal cancer staging test: A new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer,” *Mol. Diagnosis Ther.*, vol. 13, no. 1, pp. 11–14, Aug. 2009, doi: 10.1007/bf03256309.
- [217].A. Venook, “Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer,” *Oncologist*, vol. 10, no. 4, pp. 250–261, Apr. 2005, doi: 10.1634/theoncologist.10-4-250.
- [218].R. T. Prehn, “The Inhibition of Tumor Growth by Tumor Mass,” *Cancer Res.*, vol. 51, no. 1, pp. 2–4, 1991, Accessed: Apr. 03, 2021. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/1988084/>.
- [219].L. M. Brown, A. M. Malkinson, D. E. Rannels, and S. R. Rannels, “Compensatory lung growth after partial pneumonectomy enhances lung tumorigenesis induced by 3-methylcholanthrene,” *Cancer Res.*, vol. 59, no. 20, pp. 5089–5092, 1999, Accessed: Apr. 03, 2021. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/10537279/>.
- [220].B. H. Smith et al., “Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth,” *Cancer Res.*, vol. 71, no. 3, pp. 725–735, Feb. 2011, doi: 10.1158/0008-5472.CAN-10-2258.
- [221].P. H. Rooney et al., “Colorectal cancer genomics: Evidence for multiple genotypes which influence survival,” *Br. J. Cancer*, vol. 85, no. 10, pp. 1492–1498, Nov. 2001, doi: 10.1054/bjoc.2001.2095.
- [222].N. B. Janakiram and C. V. Rao, “The Role of Inflammation in Colon Cancer,” in *Advances in experimental medicine and biology*, vol. 816, Adv Exp Med Biol, 2014, pp. 25–52.
- [223].N. Suh et al., “Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats,” *Cancer Prev. Res.*, vol. 4, no. 11, pp. 1895–1902, Nov. 2011, doi: 10.1158/1940-6207.CAPR-11-0222.
- [224].P. Ungprasert, W. Cheungpasitporn, C. S. Crowson, and E. L. Matteson, “Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies,” *Eur. J. Intern. Med.*, vol. 26, no. 4, pp. 285–291, May 2015, doi: 10.1016/j.ejim.2015.03.008.
- [225].R. A. Gupta and R. N. DuBois, “Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2,” *Nat. Rev. Cancer*, vol. 1, no. 1, pp. 11–21, 2001, doi: 10.1038/35094017.
- [226].P. Jüni, L. Nartey, S. Reichenbach, R. Sterchi, P. A. Dieppe, and P. M. Egger, “Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis,” *Lancet*, vol. 364, no. 9450, pp. 2021–2029, Dec. 2004, doi: 10.1016/S0140-6736(04)17514-4.
- [227].F. E. Silverstein et al., “Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and reumatoid arthritis: The CLASS study: A randomized controlled trial,” *J. Am. Med. Assoc.*, vol. 284, no. 10, pp. 1247–1255, Sep. 2000, doi: 10.1001/jama.284.10.1247.

- [228].S. A. Sgambati, "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention: Commentary," *Diseases of the Colon and Rectum*, vol. 48, no. 6. Massachusetts Medical Society, p. 1331, Mar. 17, 2005, doi: 10.1056/nejmoa050405.
- [229].S. Lev-Ari et al., "Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells," *Clin. Cancer Res.*, vol. 11, no. 18, pp. 6738–6744, Sep. 2005, doi: 10.1158/1078-0432.CCR-05-0171.
- [230].V. Pala et al., "Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort," *Int. J. Cancer*, vol. 129, no. 11, pp. 2712–2719, Dec. 2011, doi: 10.1002/ijc.26193.
- [231].C. C. Chen et al., "Oral inoculation of probiotics *Lactobacillus acidophilus* NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue," *Br. J. Nutr.*, vol. 107, no. 11, pp. 1623–1634, Jun. 2012, doi: 10.1017/S0007114511004934.
- [232].S. S. Choi, Y. Kim, K. S. Han, S. You, S. Oh, and S. H. Kim, "Effects of *Lactobacillus* strains on cancer cell proliferation and oxidative stress in vitro," *Lett. Appl. Microbiol.*, vol. 42, no. 5, pp. 452–458, May 2006, doi: 10.1111/j.1472-765X.2006.01913.x.
- [233].B. N. P. Sah, T. Vasiljevic, S. McKechnie, and O. N. Donkor, "Effect of probiotics on antioxidant and antimutagenic activities of crude peptide extract from yogurt," *Food Chem.*, vol. 156, pp. 264–270, Aug. 2014, doi: 10.1016/j.foodchem.2014.01.105.
- [234].M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, "Free radicals and antioxidants in normal physiological functions and human disease," *International Journal of Biochemistry and Cell Biology*, vol. 39, no. 1. Pergamon, pp. 44–84, Jan. 01, 2007, doi: 10.1016/j.biocel.2006.07.001.
- [235].M. L. Circu and T. Y. Aw, "Reactive oxygen species, cellular redox systems, and apoptosis," *Free Radical Biology and Medicine*, vol. 48, no. 6. Pergamon, pp. 749–762, Mar. 15, 2010, doi: 10.1016/j.freeradbiomed.2009.12.022.
- [236].R. Guimarães, L. Barros, A. M. Carvalho, and I. C. F. R. Ferreira, "Studies on chemical constituents and bioactivity of *rosa micrantha*: An Alternative antioxidants source for food, pharmaceutical, or cosmetic applications," *J. Agric. Food Chem.*, vol. 58, no. 10, pp. 6277–6284, May 2010, doi: 10.1021/jf101394w.
- [237].I. Ferreira, L. Barros, and R. Abreu, "Antioxidants in Wild Mushrooms," *Curr. Med. Chem.*, vol. 16, no. 12, pp. 1543–1560, Apr. 2009, doi: 10.2174/092986709787909587.
- [238].P. Montero, M. M. Calvo, M. C. Gómez-Guillén, and J. Gómez-Estaca, "Microcapsules containing astaxanthin from shrimp waste as potential food coloring and functional ingredient: Characterization, stability, and bioaccessibility," *LWT - Food Sci. Technol.*, vol. 70, pp. 229–236, Jul. 2016, doi: 10.1016/j.lwt.2016.02.040.
- [239].M. Carochio et al., "Basil as functional and preserving ingredient in 'serra da Estrela' cheese," *Food Chem.*, vol. 207, pp. 51–59, Sep. 2016, doi: 10.1016/j.foodchem.2016.03.085.



- [240].Y. S. Velioglu, G. Mazza, L. Gao, and B. D. Oomah, "Antioxidant Activity and Total Phenolics in Selected Fruits, Vegetables, and Grain Products," *J. Agric. Food Chem.*, vol. 46, no. 10, pp. 4113–4117, 1998, doi: 10.1021/jf9801973.
- [241].J. Shi, H. Nawaz, J. Pohorly, G. Mittal, Y. Kakuda, and Y. Jiang, "Extraction of polyphenolics from plant material for functional foods - Engineering and technology," *Food Rev. Int.*, vol. 21, no. 1, pp. 139–166, 2005, doi: 10.1081/FRI-200040606.
- [242].U. Wenzel, S. Kuntz, M. D. Brendel, and H. Daniel, "Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells," *Cancer Res.*, vol. 60, no. 14, pp. 3823–3831, 2000, Accessed: Apr. 03, 2021. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/10919656/>.
- [243].F. Shahidi and P. Ambigaipalan, "Phenolics and polyphenolics in foods, beverages and spices: Antioxidant activity and health effects - A review," *Journal of Functional Foods*, vol. 18. Elsevier Ltd, pp. 820–897, Oct. 01, 2015, doi: 10.1016/j.jff.2015.06.018.
- [244].S. Jiménez, S. Gascón, A. Luquin, M. Laguna, C. Ancin-Azpilicueta, and M. J. Rodríguez-Yoldi, "Rosa canina extracts have antiproliferative and antioxidant effects on caco-2 human colon cancer," *PLoS One*, vol. 11, no. 7, p. e0159136, Jul. 2016, doi: 10.1371/journal.pone.0159136.
- [245].A. C. Miller, R. M. Rashid, L. Falzon, E. M. Elamin, and S. Zehtabchi, "Silver sulfadiazine for the treatment of partial-thickness burns and venous stasis ulcers," *Journal of the American Academy of Dermatology*, vol. 66, no. 5. Mosby Inc., pp. e159–e165, May 01, 2012, doi: 10.1016/j.jaad.2010.06.014.
- [246].W. Zhao, L. Liu, Y. Wang, T. Mao, and J. Li, "Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor- $\gamma$  and insulin receptor in a rat model of nonalcoholic fatty liver disease," *Exp. Ther. Med.*, vol. 11, no. 1, pp. 183–190, Jan. 2016, doi: 10.3892/etm.2015.2846.
- [247].S. Dasari and P. Bernard Tchounwou, "Cisplatin in cancer therapy: Molecular mechanisms of action," *European Journal of Pharmacology*, vol. 740. Elsevier, pp. 364–378, Oct. 05, 2014, doi: 10.1016/j.ejphar.2014.07.025.
- [248].M. Frezza et al., "Novel Metals and Metal Complexes as Platforms for Cancer Therapy," *Curr. Pharm. Des.*, vol. 16, no. 16, pp. 1813–1825, Jun. 2010, doi: 10.2174/138161210791209009.
- [249].K. Benjamin Garbutcheon-Singh et al., "Transition Metal Based Anticancer Drugs," *Curr. Top. Med. Chem.*, vol. 11, no. 5, pp. 521–542, Mar. 2011, doi: 10.2174/156802611794785226.
- [250].N. Muhammad and Z. Guo, "Metal-based anticancer chemotherapeutic agents," *Current Opinion in Chemical Biology*, vol. 19, no. 1. Elsevier Ltd, pp. 144–153, Apr. 01, 2014, doi: 10.1016/j.cbpa.2014.02.003.
- [251].S. Komeda and A. Casini, "Next-Generation Anticancer Metallodrugs," *Curr. Top. Med. Chem.*, vol. 12, no. 3, pp. 219–235, Feb. 2012, doi: 10.2174/156802612799078964.
- [252].N. J. Wheate, S. Walker, G. E. Craig, and R. Oun, "The status of platinum anticancer drugs in the clinic and in clinical trials," *Dalt. Trans.*, vol. 39, no. 35, pp. 8113–8127, Sep. 2010, doi: 10.1039/c0dt00292e.
- [253].L. A. Ibert. B. Peres and A. D. anta. da Cunha, "Acute nephrotoxicity of cisplatin: molecular mechanisms," *Jornal brasileiro de nefrologia : 'orgão oficial de Sociedades Brasileira e Latino-*

- Americana de Nefrologia, vol. 35, no. 4. Sociedade Brasileira de Nefrologia, pp. 332–340, Oct. 01, 2013, doi: 10.5935/0101-2800.20130052.
- [254].T. Karasawa and P. S. Steyger, “An integrated view of cisplatin-induced nephrotoxicity and ototoxicity,” *Toxicology Letters*, vol. 237, no. 3. Elsevier Ireland Ltd, pp. 219–227, Sep. 07, 2015, doi: 10.1016/j.toxlet.2015.06.012.
- [255].M. S. Gonçalves, A. F. Silveira, A. R. Teixeira, and M. A. Hyppolito, “Mechanisms of cisplatin ototoxicity: Theoretical review,” *Journal of Laryngology and Otology*, vol. 127, no. 6. Cambridge University Press, pp. 536–541, Jun. 2013, doi: 10.1017/S0022215113000947.
- [256].Z. H. Siddik, “Cisplatin: Mode of cytotoxic action and molecular basis of resistance,” *Oncogene*, vol. 22, no. 47 REV. ISS. 6. Nature Publishing Group, pp. 7265–7279, Oct. 20, 2003, doi: 10.1038/sj.onc.1206933.
- [257].L. Amable, “Cisplatin resistance and opportunities for precision medicine,” *Pharmacological Research*, vol. 106. Academic Press, pp. 27–36, Apr. 01, 2016, doi: 10.1016/j.phrs.2016.01.001.
- [258].D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” *Nature Reviews Drug Discovery*, vol. 4, no. 4. Nature Publishing Group, pp. 307–320, Apr. 24, 2005, doi: 10.1038/nrd1691.
- [259].P. M. Hoff et al., “Literature review and practical aspects on the management of oxaliplatin-associated toxicity,” *Clinical Colorectal Cancer*, vol. 11, no. 2. Elsevier Inc., pp. 93–100, Jun. 01, 2012, doi: 10.1016/j.clcc.2011.10.004.
- [260].A. de Gramont et al., “Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer,” *J. Clin. Oncol.*, vol. 18, no. 16, pp. 2938–2947, 2000, doi: 10.1200/JCO.2000.18.16.2938.
- [261].A. D. Lammer, M. E. Cook, and J. L. Sessler, “Synthesis and anti-cancer activities of a water soluble gold(III) porphyrin,” *J. Porphyr. Phthalocyanines*, vol. 19, no. 1–3, pp. 398–403, Jan. 2015, doi: 10.1142/S1088424615500236.
- [262].C. T. Lum, A. S. T. Wong, M. C. M. Lin, C. M. Che, and R. W. Y. Sun, “A gold(III) porphyrin complex as an anti-cancer candidate to inhibit growth of cancer-stem cells,” *Chem. Commun.*, vol. 49, no. 39, pp. 4364–4366, Apr. 2013, doi: 10.1039/c2cc37366a.
- [263].C. Hu, X. Li, W. Wang, R. Zhang, and L. Deng, “Metal-N-Heterocyclic Carbene Complexes as Anti-Tumor Agents,” *Curr. Med. Chem.*, vol. 21, no. 10, pp. 1220–1230, Mar. 2014, doi: 10.2174/0929867321666131217161849.
- [264].C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, and M. P. Rigobello, “Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells,” *Free Radic. Biol. Med.*, vol. 42, no. 6, pp. 872–881, Mar. 2007, doi: 10.1016/j.freeradbiomed.2006.12.021.
- [265].R. Galassi et al., “Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents,” *Dalt. Trans.*, vol. 41, no. 17, pp. 5307–5318, May 2012, doi: 10.1039/c2dt11781a.
- [266].A. Garcia et al., “Novel antitumor adamantane-azole gold(I) complexes as potential inhibitors of thioredoxin reductase,” *J. Biol. Inorg. Chem.*, vol. 21, no. 2, pp. 275–292, Apr. 2016, doi: 10.1007/s00775-016-1338-y.

- [267].L. Ortego et al., “Strong inhibition of thioredoxin reductase by highly cytotoxic gold(I) complexes. DNA binding studies,” *J. Inorg. Biochem.*, vol. 130, no. 1, pp. 32–37, Jan. 2014, doi: 10.1016/j.jinorgbio.2013.09.019.
- [268].P. A. Tsuji et al., “The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways,” *PLoS One*, vol. 10, no. 4, p. e0124487, Apr. 2015, doi: 10.1371/journal.pone.0124487.
- [269].D. F. D. Mahmood, A. Abderrazak, K. El Hadri, T. Simmet, and M. Rouis, “The thioredoxin system as a therapeutic target in human health and disease,” *Antioxidants and Redox Signaling*, vol. 19, no. 11. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA, pp. 1266–1303, Oct. 10, 2013, doi: 10.1089/ars.2012.4757.
- [270].P. A. Konstantinopoulos and A. G. Papavassiliou, “The potential of proteasome inhibition in the treatment of colon cancer,” *Expert Opinion on Investigational Drugs*, vol. 15, no. 9. Taylor & Francis, pp. 1067–1075, Sep. 2006, doi: 10.1517/13543784.15.9.1067.
- [271].N. Liu, H. Huang, Q. P. Dou, and J. Liu, “Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds,” *Oncoscience*, vol. 2, no. 5, pp. 457–466, 2015, doi: 10.18632/oncoscience.167.
- [272].D. Buac, S. Schmitt, G. Ventro, F. Rani Kona, and Q. Ping Dou, “Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells,” *Mini-Reviews Med. Chem.*, vol. 12, no. 12, pp. 1193–1201, Sep. 2012, doi: 10.2174/138955712802762040.
- [273].X. Zhang et al., “Inhibition of tumor proteasome activity by gold-dithiocarbamate complexes via both redox-dependent and -independent processes,” *J. Cell. Biochem.*, vol. 109, no. 1, pp. 162–172, Jan. 2010, doi: 10.1002/jcb.22394.
- [274].E. García-Moreno, S. Gascón, E. Atrián-Blasco, M. J. Rodríguez-Yoldi, E. Cerrada, and M. Laguna, “Gold(I) complexes with alkylated PTA (1,3,5-triaza-7-phosphaadamantane) phosphanes as anticancer metallodrugs,” *Eur. J. Med. Chem.*, vol. 79, pp. 164–172, May 2014, doi: 10.1016/j.ejmech.2014.04.001.
- [275].E. Garcia-Moreno et al., “In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br,” *Anticancer. Agents Med. Chem.*, vol. 15, no. 6, pp. 773–782, Jun. 2015, doi: 10.2174/1871520615666150129211440.
- [276].E. García-Moreno et al., “In vitro and in vivo evaluation of organometallic gold(i) derivatives as anticancer agents,” *Dalt. Trans.*, vol. 45, no. 6, pp. 2462–2475, Feb. 2016, doi: 10.1039/c5dt01802a.
- [277].E. Atrián-Blasco, S. Gascón, M. J. Rodríguez-Yoldi, M. Laguna, and E. Cerrada, “Synthesis of Gold(I) Derivatives Bearing Alkylated 1,3,5-Triaza-7-phosphaadamantane as Selective Anticancer Metallodrugs,” *Eur. J. Inorg. Chem.*, vol. 2016, no. 17, pp. 2791–2803, Jun. 2016, doi: 10.1002/ejic.201600177.